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ABSTRACT 
Keloids are classically regarded as scars that `outgrow the boundary of the original injury'. 
Ambiguous data concerning certain characteristics of keloid fibroblasts (such as proliferation 
rates and collagen production), however, have served only to confuse researchers. The lack 
of an in vivo model and of detailed clinical accounts are added problems. In this study, a 
murine granulomatous tissue resolution model was used to investigate the profile of a 
number of cytokines suspected to be involved in the aetiology of keloids. 
The results obtained from these experiments were then extrapolated to clarify the 
observations made in keloids. The results of these extrapolated comparisons revealed 
elevated levels of interleukin (IL)-4, IL-10, vascular endothelial growth factor (VEGF), 
epidermal growth factor (EGF), platelet-derived growth factor (PDGF), basic fibroblast 
growth factor (bFGF) and transforming growth factor beta (TGF)-ß in keloid samples and 
decreased levels of interferon (IFN)-y and IL-2. 
The murine model was also used to investigate the implications of the low levels of 
IFN-y known to be present in the serum of keloid patients and shown here to be present in 
clinical samples. The results were found to support the hypothesis that the addition of IFN-y 
reduces the fibrosis so typical of keloids by rectifying the abnormality of the absence of IFN- 
y content. The same model was used to provide evidence that the inhibition of VEGF activity 
in resolving wounds may halt the development of keloid lesions. 
The immunohistochemical profiles of cellular proliferation, apoptosis, lymphokines 
and cytokines for resolution (and, to a certain extent, the model) were used to compare with 
the abnormally resolved wounds which were available as clinical samples. 
Immunohistochemistry was also employed to describe the cellular nature of the clinical 
tissue samples in detail and to facilitate the development of the following hypothesis for 
keloid formation and propagation: lymphocytes migrate to the site of an (alleged) 
endogenous antigen present in the skin. The nature of these lymphocytes is characteristic of a 
type 2 immune response, they produce IL-4 (and IL-10) which in turn inhibit(s) the 
production of IFN-y and IL-2. Aside from this immunological response, wound resolution is 
taking place: fibroblasts are producing PDGF, EGF and TGF-ß to aid matrix remodelling 
and collagen synthesis. The provisional matrix is being vascularised by the action of VEGF, 
to allow the replenishment of nutrients; regression of blood vessels occurs through the action 
of an apoptosis-dependent mechanism, as does the `normalisation' of fibroblastic 
populations. The keloid scar continues to grow after the cessation of resolution because the 
immune response to the `endogenous' antigen continues and the lymphocytes continue to 
migrate to the site of the wound and continue to stimulate fibroblast proliferation and 
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Chapter 1 
1.10 WOUND HEALING 
Under normal conditions, in normal individuals, the body's response to injury 
whether the injury is induced surgically or traumatically is immediate and 
effective. Cutaneous wound healing is a natural mechanism which operates 
optimally in most circumstances and generally requires no therapeutic 
intervention. Research carried out in this area aims to elucidate each step, and 
all components thereof, from the infliction of the injury through to the 
resolution of the wound. Some workers aim to develop therapies which will 
provide routes resulting in scarless healing; in adult tissue, with our current 
understanding, however, this would mean no healing at all. 
Not all wounds are equal. This is a fact better understood by clinicians 
and surgeons than by researchers. The infliction of the injury dictates the 
subsequent healing process: first intention healing occurs quickly with 
minimal granulation tissue and scar formation (granulation tissue is 
characterised by the large-scale regeneration of the tissue microvasculature 
and the reinstatement of macrophage, lymphocyte and fibroblast populations) 
and is generally associated with surgical cuts or small skin wounds; second 
intention healing (which the work in this thesis is concerned with) occurs with 
granulation tissue formation, wound contraction and reepithelialisation, the 
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scar formed is less cosmetically acceptable than that formed as a result of first 
intention healing and infection and/or tissue loss may be involved; third 
intention healing occurs when wound closure is hampered or delayed by 
prolonged debridement or by the application of treatment, respectively (for 
reviews, see Bertone, 1989 x2). 
Simplistically, wound healing can be viewed as a three step process 
(for review, see Clark, 1993): inflammation; tissue regeneration; and tissue 
reorganisation. Each step is highly organised and complex with numerous 
components. The three steps overlap and the terminology is used by 
researchers to allow visualisation and to provide order (any time periods given 
for healing processes are approximations only and tend to vary from individual 
to individual and injury to injury). 
Step 1: Inflammation 
Inflammation is an area of research in itself and will not be described in great 
detail here. It involves the prevention of extensive blood loss and the closing 
of the wound via clot and scar formation. Reepithelialisation, 
neovascularisation and decontamination by phagocytosis occur. The 
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inflammatory phase, if it proceeds without complication, takes place in the 
first four days post-injury (Hardy, 1989). 
Step 2: Tissue regeneration 
Four days post-injury, the neodermis begins to form. The behaviour of the 
granulation tissue which consists of newly formed blood vessels, 
macrophages, fibroblasts and loose connective tissue is directed by the 
interaction of a procession of cytokines with the provisional matrix (Raghow, 
1994). The regeneration process takes approximately three weeks with wound 
contraction occurring between seven and fourteen days. Collagen type III has 
been detected in human skin wounds as early as 2-3 days post injury (Betz et 
al, 1993), but the majority of it is quickly replaced by the highly cross-linked 
collagen type I by approximately day seven or eight. Type I procollagen is 
absent from fibroblast granules by day nine or ten (Moulin, 1995). 
Step 3: Tissue reorganisation 
This stage of healing can continue for months or even years. Early phases 
involve scar formation and an increase in wound strength, the latter effect 
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being caused by the realignment and rearrangement of collagen fibres. 
Subsequent phases involve a decrease in the number of cellular populations 
present within the wound, blood vessel regression and collagen remodelling, 
all of which result in the injured area becoming more like normal tissue in 
appearance and structure (Hardy, 1989). 
It is not intended to give a detailed account of every aspect of cutaneous 
wound healing here but, for the purpose of this thesis, it is necessary to explain 
the importance of certain components of the process. These components are as 
follows: angiogenesis; fibroblasts; collagen; and mast cells. 
1.11 The role of angiogenesis in wound healing 
Angiogenesis is the process of new blood vessel formation. Although adult 
cutaneous vasularisation is generally quiescent, adult skin has the ability to 
initiate neovascularisation in response to pathological stimuli (termed 
secondary angiogenesis; Detmar, 1996). In the context of healing wounds, the 
role of secondary angiogenesis is to supply the injured area with oxygen and 
nutrients. This is a very important role. In fact, Hunt and Van. Winkle went as 
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far as to say, ̀ as neovascularisation goes, so goes the wound' (Hunt and Van 
Winkle, 1976). 
Angiogenesis begins as early as two days post-injury, new blood 
vessels at the wound site arise from existing vessels bordering the damaged 
area. Hyperpermeability of microvessels always precedes and accompanies 
angiogenesis (Dvorak et al, 1995 x2). Endothelial cells become activated and 
then undergo migration, which occurs within a provisional matrix which 
endothelial cells are able to synthesise as they proceed (Folkman and Shing, 
1992). Migration of endothelial cells is followed by proliferation, which 
ultimately occurs within the neovasculature because endothelial cells at the tip 
of the capillary do not divide (Ausprunk and Folkman, 1977). The newly 
formed vessels transport nutrients and oxygen throughout the tissue. As 
healing progresses and the injured tissue is repaired, the capillaries regress and 
the area begins to resemble normal tissue once more. 
Research carried out to study angiogenesis by the use of tumours has 
indicated that the local inhibition of new blood vessel formation may be 
therapeutic. Detmar (1996) suggested that there are currently more than 300 
ongoing clinical trials testing angiostatic agents for the treatment of human 
cancers. The suggestion that certain inflammatory skin pathologies, such as 
psoriasis, are aided by a tumour-like ability to promote enhanced angiogenesis 
is not new (Dvorak, 1986). Could this theory be developed to include 
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cutaneous healing abnormalities? Angiogenesis is essential to inflammation 
and wound healing, and any malfunction could have far-reaching effects. 'In 
view of this, Detmar (1996) suggested that psoriasis could be treated by the 
inhibition of angiogenesis, and that certain pathologies featuring delayed 
wound healing could benefit from the induction of angiogenesis. 
1.12 The role of fibroblasts in wound healing 
A great deal of work carried out over many years has established that, during 
wound healing, fibroblast populations progress through four different 
phenotypes (Welch et al, 1990; for review, see Clark, 1993): proliferative; 
migratory; synthetic (synthesising extracellular matrix components); and 
contractile (now termed myofibroblasts; Gabbiani et al, 1971; Hirschel et al, 
1971; Gabbiani et al, 1972; Ryan et al, 1974). 
During the first three days post-injury, fibroblasts in the subcutaneous 
tissue beneath the cutaneous wound proliferate, on day four they move quickly 
into the wound (Knox et al, 1986). It is thought that fibronectin receptors 
expressed in the first three days prohibit migration, and it is unclear whether or 
not migratory fibroblasts are able to proliferate. Once established within the 
wound, the fibroblasts begin to deposit collagen and fibronectin (Welch et al, 
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1990). Collagen I production is maximal at day seven; around this time, cell- 
matrix connections are formed and fibronectin receptors reappear. By 
approximately day nine, collagen synthesis has arrested and fibroblasts, which 
are now of the contractile phenotype (myofibroblasts), are anchored and 
aligned along the deposited collagen fibres. Contraction takes place between 
days seven and fourteen and occurs as the attached fibroblasts retract their 
pseudopodia (Bell et al, 1983). The ultimate fate of the wound myofibroblasts 
when their activities are completed is now recorded to be apoptosis 
(Desmouliere et al, 1995). 
It is clear that the fibroblast is a very important component of wound 
healing. The data underlying the above preview of the general activities of 
fibroblasts in the wound are impressive with respect to order and efficiency. In 
vitro studies using fibroblasts have illustrated the consistency of fibroblasts in 
continuing their functions in a variety of conditions, as cells they are resilient 
and adaptable (for review, see Clark, 1993). It is now widely accepted that 
cytokines are a modulatory influence (perhaps even the most important 
influence) on the behaviour of fibroblasts, whether in situ or ex situ. 
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1.13 The role of collagen in wound healing 
To date, numerous collagen subtypes have been identified. Six of which have 
been definitively identified in skin: types I, III, V and VI are interstitial 
collagens; types IV and VII are found in basement membranes. 
Immunohistochemical localisation has been used to analyse the time- 
dependent appearance of each of these types of collagen throughout the wound 
healing process (Vialle-Presles et al, 1989; Betz et al, 1992 x3; Betz et al, 
1993; Oono et al, 1993). Collagen III appears as early as 48 hours post-injury 
(Kurkinen et al, 1980), it is thought to be involved in the process of wound 
contraction (Ehrlich, 1988). Procollagen type III is present for approximately 
two or two and a half days. Immunolabelling for collagen type III in wound 
samples often indicates a wound age of less than six days (Betz et al, 1993). 
Type I procollagen can be detected in cytoplasmic granules once 
fibroblasts have migrated into the wound; when the collagen matrix has 
accumulated, type I procollagen disappears (usually by day nine or ten; for 
review, see Clark, 1993). Changes in the alignment of collagen fibres 
strengthen the wound, and within approximately two weeks all collagen type 
III is completely replaced by the stronger, more mature collagen type I. By the 
end of the three weeks, the amount of collagen present has long since 
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plateauxed but the tensile strength is still only 15% of that of normal tissue 
(Howes and Harvey, 1929; Levenson, 1962). 
Remodelling of the newly synthesised area can continue for years; 
collagen synthesis and breakdown occurs at elevated rates compared with that 
of the site prior to injury, although there is evidence that neighbouring tissues 
also show enhanced collagen turnover (Merritt et al, 1975; for review, see 
Hardy, 1989). 
1.14 The role of mast cells in wound healing 
Mast cells have been found in elevated numbers in pulmonary fibrosis, 
keloids, hypertropic scars, scleroderma and wound healing. These 
observations have led to increased interest in the role of mast cells in fibrosis 
and their possible interactions with fibroblasts (for review, see Claman, 1985). 
Mast cells are resident in skin, they produce interleukin 4 (Bradding et 
al, 1992) and `degranulate' to release mediators when activated through the 
cross-linking of their high-affinity immunoglobulin E receptors by antigen. In 
vitro, mast cell survival and growth is enhanced by interleukins 3,4 and 10 
alone and in synergy (Thompson-Snipes et al, 1991; Tsuji et al, 1995). The 
presence of mast cells in co-culture with fibroblasts enhances the migration 
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and proliferation of fibroblasts into artificial wounds (Levi-Schaffer and 
Kupietzky, 1990). Activated mast cells induce fibroblast proliferation and 
collagen production (Levi-Schaffer and Rubinchik, 1995). 
Kinetic studies have demonstrated that mast cell numbers fall early in 
the wound healing process but after one or two weeks there is a great increase 
in numbers. This initial decrease may be caused by emigration, but it is more 
likely to be caused by degranulation taking place in the early stages of healing. 
This hypothesis is consistent with the suggestion of mast cell degranulation 
being the early source of interleukin 4 release during the development of an 
immune response, and that the later source of interleukin 4 release is 
lymphocytes (for review, see Claman, 1985). There is also evidence that the 
activation of mast cells coincides with the initiation of skin fibrosis in some 
diseases (Claman, 1985). In this case it is possible that the mast cells are 
providing substances which promote fibrosis, such as histamine (Claman, 
1985). 
Studies of T cell, mast cell and fibroblast interactions during wound 





Cytokines are relatively small secreted regulatory polypeptides which control 
the growth, differentiation and functions of tissue cells. They are protease- 
resistant, soluble and stable (probably because of their general structure which 
includes protective carbohydrates and disulphide bonds). Almost all are found 
extracellularly and interact with specific target cells. Their production is 
specific, they are transient, rarely found in the circulation, and they have high 
biological redundancy. 
Producer cells respond to an external stimulus and initiate the 
appropriate response in neighbouring target cells through the action of 
cytokines. Or, as is the case in the nervous system, a constitutive level of 
cytokine production may be necessary for cell survival and selection. 
Experiments with cytokine gene knockout mice (Tavernier, 1993) have 
demonstrated that very few cytokines are essential to life - there are many 
others which are suited to compensate for absences. Cytokines, therefore, are 
now generally accepted as being widely pleiotropic in action. 
Another important characteristic of cytokines and their actions is 
secondary production. Cytokines can stimulate the production, by target cells, 
of positive and negative regulatory cytokines in an autocrine or paracrine way 
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(Arai et al, 1990). Because of the pleiotropic behaviour of cytokines, however, 
it is very difficult to study secondary production or, indeed, any cytokine 
action in vivo (for review, see Carter and Swain, 1997). Serum levels of 
cytokines are rarely detectable. Reasons for cytokine elusiveness include the 
close proximity of target and responder cells (Metcalf, 1991), the fact that 
production is directional and in small quantities (Poo et al, 1988), the 
destruction of the cytokine by the target cell (Nicola et al, 1988), the possible 
binding of the cytokine to extracellular matrix components (Gordon, 1991), 
and the incidence of high levels of circulating soluble cytokine receptors 
(Femandez-Botran, 1991; Arend, 1993; for a general overview, see Nicola, 
1994). 
1.21 Cytokines and T cells 
It is now well established that murine and human CD4+ and CD8+ T cells exist 
as subsets (for review, see Romagnani, 1991; Paul and Seder, 1994; Mosmann 
and Sad, 1996). Moreover, these subsets have defining characteristic ytokine 
secretion patterns and are associated with certain pathological conditions. The 
type 1 and type 2 subsets interact with one another through cross-regulation. It 
has been suggested that this attribute will provide a means to manipulate 
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lymphocytes and the subsequent immune responses in the context of certain 
pathologies and to improve the overall condition of patients. 
Antigenic stimulation leads to a transient burst of cytokine production 
by activated T cells. The nature and concentration of the antigen dictates the 
pattern of cytokine production, in nonpathological situations. Levels of type 1 
cytokines, such as interleukin 2 and interferon gamma, are elevated in efficient 
responses against intracellular pathogens, whereas type 2 cytokines, such as 
interleukins 4 and 10, are elevated in allergic responses and helminth 
infections. Type 1 cytokines activate macrophages, increase antigen 
presentation, phagocytosis, macrophage killing of intracellular pathogens, and 
are involved in delayed-type hypersensitivity responses and long-term 
immunity. Type 2 cytokines increase immunoglobulin E expression and mast 
cell and eosinophil degranulation in response to metazoan parasites, which is 
not always beneficial to the host (for review, see Powrie and Coffman, 1993). 
It is not clear how the immune response matches the type 1 or type 2T 
cell response to a particular pathogen (Mosman and Sad, 1996). Perhaps the 
soluble or particulate nature of the antigen or even its concentration (type 1 
responses are associated with moderate doses of antigen, type 2 responses are 
associated with a range of doses) has some influence over the immune 
polarisation. Some researchers report that antigens stimulate a type 1, type 2 
14 
Chapter 1 
and type 1 pattern chronologically, whereas others report that the pattern is 
type 2, type 1 and type 2 (Mosman and Sad, 1996). 
Skin-generated immunity is dominated by T cells, they mediate some 
delayed-type hypersensitivity responses (which can descibed as type 1 
responses) and some atopic responses (which can be said to feature type 2 
responses). Antigen presenting cells which are resident in the skin are as 
follows: Langerhans' cells in the epidermis and dendritic cells and 
macrophages in the dermis (Zierhut et al, 1996). y/6 T cells are a prominent 
population within epithelial tissues such as skin but knowledge of their 
function and specificity is poor. They share features with innate immunity 
cells and respond much faster to antigenic stimulation than do a/ß T cells, 
which suggests that their response influences the subsequent cytokine 
production by the late a/ß T cell arrivals. There is also evidence that y/S T 
cells exist in type 1 and 2 subsets (Boismenu and Havran, 1997). 
CD8+ T cells also feature type 1 and type 2 subsets, the major 
difference between CD8+ and CD4+ T cell subsets is that once the type has 
been set for CD8+ cells it cannot be reversed (Mosman and Sad, 1996). They 
are associated with the same cytokine profiles as are CD4+ T cells, although it 
appears that CD8+ T cells favour the development of the type 1 subset and that 
more interleukin 4 is required to develop the type 2 subset. 
15 
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Both type 1 and type 2 CD8+ T cells are thought to be cytolytic. 
Killing of infected cells by CD8+ T cells does not occur through the effects of 
cytokine secretion, however, it usually occurs through apoptosis (Carter and 
Dutton, 1996). 
To date, the only cell marker which allows the differentiation of type 1 
and type 2 subsets is CD30 (CD, cluster of differentiation). Both subsets have 
been documented to express it, but expression by type 2 cells is thought to be 
much stronger and more sustained; indeed, a rare CD30+ population has been 
found to contain cells specific for a recently exposed allergen (see, Mosman 
and Sad, 1996), a situation associated with type 2 responses. The mechanism 
of the differentiation of T cells into the CD4+ and CD8+ subsets is thought to 
be the same, with the cross-linkage of the CD30 marker stimulating type 2 
cells preferentially (Carter and Dutton, 1996). And it appears that repeated 
antigenic stimulation drives the immune response towards the type 2 subset 
(Carter and Dutton, 1996). 
Now that it has become possible to classify the T cell subsets involved 
in immune reactions by the detection of CD30 expression and cytokine 
secretion patterns, it may also be possible to suggest methods of therapeutic 
intervention. 
Although it has not yet been documented which T cell subset(s) is/are 
involved in each wound healing stage, there are many opportunities for control 
16 
Chapter 1 
via cytokine neutralisation or cytokine administration (for review, see 
Miossec, 1993; Powrie and Coffman, 1993). For example, the beneficial 
effects of the administration of interferon gamma to hypertropic scars and the 
administration of interleukin 4 to schleroderma patients (Miossec, 1993). 
1.22 Cytokines and wound healing 
Because wound healing involves the growth, interaction, differentiation and 
activity of cells and because the release and action of cytokines is the 
mechanism of communication between responding and target cells, much 
work has been done to elucidate each finite step connecting cytokine 
expression and appearance with the effects of subsequent cellular responses in 
the healing process (for reviews, Kovacs and DiPietro, 1994; Slavin, 1996). 
Many reviews and primary publications have attempted to elucidate the role of 
cytokines in healing, but have generally focused on `growth factors' such as 
transforming growth factor beta, with `lymphokines' such as interleukin 2 




Interferon gamma is produced by T cells (specifically CD8+ cells and types 1 
and 0 CD4+ cells [type 0 CD4+ T cells are those which are classified as being 
neither type 1 nor type 2. It is unclear whether this subset represents an initial 
subset consisting of all CD4+ T cells prior to type 1/type 2 differentiation or if 
it represents a third distinctive and individual subtype]) and natural killer cells 
(Farrar and Schreiber, 1993). Interferon gamma antibodies protect mice 
against the generalised Schwartzman reaction (a hypersensitivity reaction 
induced by lipopolysaccharide administration; Billiau et al, 1987). 
Interferon gamma is synthesised and secreted via antigen stimulation 
of T cells; maximal synthesis occurs 12-14 hours following stimulation. It has 
an antiproliferative effect on tumour cells (Farrar and Schreiber, 1993) and 
enhances immunoglobulin secretion by B cells (see Nicola, 1994). Interferon 
gamma also causes nonspecific cell-mediated responses and is necessary for 
the resolution of microbial infections (Farrar and Schreiber, 1993; Buchmeier 
and Schreiber, 1985) and has been implicated in the development of 
autoimmune disease (Sarvetnick et al, 1988). 
T cells mainly produce interferon gamma in response to soluble 
antigens (for review, see Trinchieri and Perussia, 1985), which induces similar 
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effects to that of the adaptive immune system. Mast cells and fibroblasts 
express interferon gamma receptors, as do other cells (for review, see Hill et 
al, 1992). 
Interferon gamma and wound healing 
Interferon gamma downregulates angiogenesis in vitro in a dose-dependent 
manner via the inhibition of endothelial cell proliferation and growth (Sato et 
al, 1990; Tsuruoka et al, 1988). It inhibits collagen lattice contraction and 
delays wound closure in vitro (Granstein et al, 1989; Dans and Isseroff, 1994). 
Work carried out in vitro and by immunohistochemistry, immunofluorescence 
and Western blotting has shown that interferon gamma increases the 
production by fibroblasts of glycosaminoglycans and collagenase (Duncan and 
Berman, 1989). It has been shown to decrease alpha smooth muscle actin 
mRNA and protein levels and the proliferation of human fibroblasts in vitro 
(Desmouliere eta!, 1992). 
Interferon gamma can act in a proinflammatory or anti-inflammatory 
way, depending on the model being used (Heremans et al, 1989; Granstein et 
al, 1989), it decreases collagen synthesis in vivo (Granstein et al, 1989; 
Granstein et al, 1990; Guruyjeyalakshmi and Giri, 1995) possibly via the 
19 
Chapter 1 
downregulation of transforming growth factor beta mRNA expression 
(Guruyjeyalakshmi and Giri, 1995). This modulation of transforming growth 
factor beta mRNA activity could explain the ability of interferon gamma to 
decrease extracellular matrix component release, collagen synthesis, 
angiogenesis, wound contraction and its ability to increase collagenase 
synthesis. Kovacs and DiPietro (1994) suggest that interferon gamma may 
function as an endogenous mediator to terminate the collagen synthesis phase 
of wound healing. Its appearance early and late in the wound healing process, 
although not in the middle stages, reiterates this suggested influence. 
Interleukin 2 
The most important function of interleukin 2 is growth promotion of T cells 
(for review, see Smith, 1980; Nicola, 1994). It is synthesised and secreted in 
response to the activation of T cells. Antigen-specific effector cells are then 
generated via the binding of autocrine and paracrine interleukin 2 to its 
receptor. Interleukin 2 knockout mice demonstrate normal thymocyte and 
peripheral T cell development (Schorle eta!, 1991; Kundig et al, 1993). 
Interleukin 2 also has a role in the differentiation of T cells and is able 
to stimulate the production of itself and of interferon gamma (Farrar et al, 
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1982; Howard et al, 1983). Interleukin 2 is also able to induce an 
inflammatory response by the activation of natural killer cells (for review, see 
Oleksowicz et al, 1994) and to increase immunoglobulin production by B cells 
(for review, see Hill et al, 1992). 
Interleukin 4 is a homeostatic regulator of interleukin-2-induced 
interferon gamma production; that is, the production of interferon gamma by 
interleukin-2-stimulated cultures is inhibited by the addition of recombinant 
interleukin 4 (Bello-Fernandez et al, 1991). 
Interleukin 2 and wound healing 
Very little work has been carried out in the area of interleukin 2 action in 
wound healing. Although, an in vivo study carried out in rats demonstrated 
increased fresh and fixed wound breaking strength and increased collagen 
synthesis (as measured by hydroxyproline content levels). This enhancement 
was attributed to the induction of secondary cytokine production in response to 
the interleukin 2 stimulation of T cells (Barbul et al, 1986). 
Most of the in vivo work carried out using interleukin 2 has centred on 
its ability to induce lymphocyte-activated killer cells to destroy cancer cells 
21 
Chapter 1 
(for review, see Hill et al, 1992). Clinical trials have provided positive results 
but it is clear that the administration of interleukin 2 alone is toxic to patients. 
Interleukin 4 
Interleukin 4 is primarily produced by T cells, it induces immunoglobulin 
class switching to immunoglobulin E expression, augments immunoglobulin 
Gl production (Finkelman et al, 1990; Kuhn et al, 1991) and is a vital 
component of T cell subset differentiation into type 2 and away from type 1 
(Sadick et al, 1990; Swain et al, 1990; Abehsira-Amar et al, 1992; Chatelain 
et al, 1992; Kopf et al, 1993). Mast cells, basophils and natural killer 1.1+ cells 
also produce interleukin 4 (Scott et al, 1990; Seder et al, 1991; Bradding et al, 
1992; MacGlashan et al, 1994). It has been suggested that either one of these 
cell types could provide the initial pulse of interleukin 4 release which is 
required for the development of the type 2T cell clones (Scott et al, 1990; 
Flamand et al, 1990; Bradding et al, 1992; Schroeder et al, 1995; Huels et al, 
1995). Cross-linkage of the T cell receptor and the immunoglobulin E receptor 
is a requirement for the induction of interleulcin 4 release by T lineage, mast or 
basophil cells (for review, see Nicola, 1994). 
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Interleukin 4 also has potent antitumour action in vivo (Tepper et al, 
1989; Golumbek et al, 1991). The discovery of this activity has led to clinical 
trials, the results of which have been promising. The therapeutic ability of 
interleukin 4 seems to lay in the induction of cytotoxic eosinophil activity 
(Tepper et al, 1992) and immunity involving tumour-specific cytotoxic T cells 
(Golumbek et al, 1991). 
Interleukin 4 and wound healing 
In vitro data indicate that interleukin-4-stimulated collagen synthesis by 
dermal fibroblasts occurs in a dose-dependent manner. Under certain 
conditions it has been documented to be more potent in stimulating the release 
of collagen than is transforming growth factor beta (Fertin et al, 1991). Indeed, 
fibroblasts do express interleukin 4 receptors (Lowenthal et al, 1988) and have 
been shown to proliferate in response to its presence (Monroe et al, 1988), and 
interleukin 4 has been shown to be fibroblast chemotactic (Postlethwaite and 
Seyer, 1991). Postlethwaite and co-workers (1992) have also demonstrated 
that dermal fibroblasts are stimulated to produce collagen types I and III and 
fibronectin in response to interleukin 4. 
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The implication of this evidence, with respect to cutaneous wound 
healing, is that interleukin 4 can be classified as a `fibrogenic' cytokine. That 
is, in addition to the clinical role that interleukin 4 has in inflammation, 
immune response development and immunoglobulin class switching, it could 
have great influence on the matrix deposition, tissue regeneration and tissue 
reorganisation components of wound resolution. 
Interleukins 4 and 10 synergise to inhibit type 1 T-cell-mediated 
immunity in vivo, although not via interferon gamma inhibition (Powrie et al, 
1993). Interleulcins 3,4 and 10 synergise to enhance the survival of mast cells 
in vitro (Tsuji et al, 1995). Interleukin 4 inhibits interferon gamma production; 
and immunoglobulin E production by normal human lymphocytes induced by 
interleukin 4 is suppressed by interferon gamma (Pene et al, 1988). 
Interleukin 10 
Interleukin 10 inhibits the proliferation of type 0,1 and 2T cells in humans 
(for review, see De Vries, 1995). It does not inhibit interleukin-2-induced T 
cell proliferation, although interleukin 2 produced by resting and activated T 
cells is inhibited by interleukin 10 at the mRNA and protein level (De Waal et 
al, 1993). Interleukin 2 is released four hours after activation and interleukin 
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10 is released 24 hours after (De Waal et al, 1991; Yssel et al, 1992; 
Mosmann, 1994). 
In humans, interleukin 10 is produced by and downregulates the 
functions of type 1 and type 2T cells. It inhibits antigen-induced production of 
interferon gamma by type 1T cells and of interleukin 4 by type 2T cells (Del 
Prete et al, 1993). Interleukin 10 is a natural suppresser of irritant skin 
responses via the inhibition of inflammatory cytokines (Berg et al, 1995). 
Interleukin 10 and wound healing 
Interleukin 10 is produced by mast cells and keratinocytes (Moore et al, 1990; 
Rivas and Ullrich, 1992; Euk and Katz, 1992). It inhibits collagen type I 
release by fibroblasts and fibroblast proliferation (Van Vlasselaer et al, 1993). 
At the mRNA level interleukin 10 increases collagenase production and 
decreases collagen type I production (Reitamo et al, 1994). 
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Epidermal growth factor and wound healing 
Epidermal growth factor is a mitogen for fibroblasts and epithelial cells and is 
present in normal human skin and keratinocytes (Nanney et al, 1984; Laato et 
al, 1987; Nickoloff et al, 1988; Grant et al, 1992). It increases collagen 
production via the stimulation of the proliferation of granulation tissue 
fibroblasts (Laato et al, 1987). Epidermal growth factor decreases the amount 
of hydroxyproline in cultured cells, which is commonly used as a measure of 
collagen content, but actually increases the overall collagen level presumably 
through the increased number of fibroblasts present. 
It has been shown to enhance reepithelialisation in partial thickness 
wounds in a dose-dependent manner and increases the thickness of the 
neodermis (Nanney, 1990). In clinical trials in human partial thickness 
wounds, however, there was no significant difference between control and 
treated sites (Cohen et al, 1995). 
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Platelet-derived growth factor in wound healing 
Platelet-derived growth factor is produced by fibroblasts, smooth muscle cells, 
macrophages/monocytes and platelets (for review, see Ross et al, 1990). 
Platelet-derived growth factor reversed radiation effects on wound 
healing in rats (Mustoe et al, 1989); wound breaking strength increased by 
50% and was attributed to fibroblast migration rather than to collagen 
production (Tan et al, 1995). It increases collagenase synthesis in cultured 
human fibroblasts (Bauer et al, 1985) and granulation tissue deposition in full 
thickness guinea pig wounds (Hill et al, 1991) and in wounds featuring a 
Hunt-Schilling chamber (Schilling et al, 59; Grotendorst et al, 1985). It 
increases the influx of procollagen-containing fibroblasts between days 2 and 
21 in wound healing experiments but its effects are transient, there are no 
known differences between control and treated wounds when healing has been 
completed (Deuel and Kawahara, 1991). 
Platelet-derived growth factor increases neovascularisation but has no 
effect on endothelial cells; it increases reepithelialisation but has no 
demonstrable effect on keratinocytes (Deuel and Kawahara, 1991). 
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Basic fibroblast growth factor and wound healing 
Basic fibroblast growth factor has a different nature compared with other 
growth factors such as epidermal growth factor, platelet-derived growth factor 
and transforming growth factor beta because it is not released into the 
extracellular space in a soluble form (for reviews, see Gospodarowicz, 1990; 
Nicola, 1994). It exists intracellularly and its mechanism of release is 
unknown. It binds heparin sulphate strongly and is mainly found bound to it in 
the extracellular matrix. It has been shown that the association between basic 
fibroblast growth factor and heparin sulphate is so intimate that the formation 
of their complex is a prerequisite for binding to the basic fibroblast growth 
factor receptor. It is from its position in the extracellular matrix that basic 
fibroblast growth factor exerts its mitogenic effects on fibroblasts, endothelial 
cells and other cell types. The mitogenic action of basic fibroblast growth 
factor correlates with its appearance in the nucleus where it tends to localise, 
rather than in the cytoplasm. This nucleic localisation follows cytoplasmic 
synthesis or internalisation. 
Basic fibroblast growth factor has a vital role in healing, it is released 
from damaged cells and induces proliferation. It increases granulation tissue 
formation and accelerates wound healing and reepithelialisation. In vitro it has 
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been shown to increase collagenase levels and to have no effect on collagen 
content when added alone; when added along with transforming growth factor 
beta, however, collagenase levels were decreased (Edwards et al, 1987). Pierce 
et al (1992) found that basic fibroblast growth factor induced an angiogenic 
response which delayed wound maturation and suggested that its presence may 
cause the ̀ loss' of some signal which initiates the cessation of repair. 
Basic fibroblast growth factor is produced by T cells, platelets, 
keratinocytes, fibroblasts, macrophages and endothelial cells. It is found in the 
sweat glands of normal human skin (Cordon-Cardo et al, 1990). It stimulates 
the release of collagenase, also in human skin (Buckley-Sturrock et al, 1989). 
It is a mitogen for endothelial cells but does not directly stimulate 
angiogenesis (Knighton et al, 1990). Work in an in vivo model showed that 
basic fibroblast growth factor decreases DNA, protein and collagen content 
(Broadley et al, 1989). 
It has been suggested that the release of heparanase from platelets or 
neutrophils may be the stimulation for basic fibroblast growth factor release 
from its complex with heparin sulphate in the extracellular matrix (Ishai- 
Michaeli et a1,1990). 
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Vascular endothelial growth factor 
Vascular endothelial growth factor is unique among growth factors in its 
specificity, its mechanism of release and its distribution (for reviews, see 
Klagsbrun and Soker, 1993; Dvorak et al, 1995). It initiates the 
hyperpermeability of blood vessels and neovascularisation and can enhance 
any process which involves angiogenesis, for example tumour growth (Plate et 
al, 1992; Jin Kim et al, 1993), rheumatoid arthritis (Koch et al, 1994), 
inflammation (Dvorak et al, 1995) and wound healing (Brown et al, 1992). It 
is a potent mitogen for endothelial cells and it appears that it is totally 
endothelial-cell-specific in its action. 
Vascular endothelial growth factor is expressed by keratinocytes 
(Ballaun et al, 1995) and there is no evidence that endothelial cells actually 
produce it; it is thought that, once released, it is taken up by endothelial cells. 
It is not thought that the cells of blood vessels release it and it has been shown 
that it is only expressed during active angiogenesis. During tumour growth, 
tumour cells close to the blood vessels express it. Vascular endothelial growth 
factor does not actually have any direct positive or negative effects on tumour 
cells, its control is exerted purely through its action on the process of 
angiogenesis. It is a heparin-binding growth factor and may be released from 
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sites in the extracellular matrix during wound healing in much the same way 
as is basic fibroblast growth factor. 
The mechanism of release is not known, but, in tumour growth, it is 
thought that hypoxia is the stimulus. 
The expression of receptors for vascular endothelial cell growth factor 
are confined to the endothelial cells of proliferating blood vessels. 
Transforming growth factor beta and wound healing 
Briefly stated, the role of transforming growth factor beta in wound healing is 
to `protect' the extracellular matrix and connective tissue: it increases 
extracellular matrix deposition, decreases proteolytic enzyme release and 
increases proteolytic enzyme inhibitor release (for review, see Nicola, 1994). It 
is released by platelets, activated macrophages and monocytes. It has both 
proinflammatory and anti-inflammatory actions and is chemotactic for 
monocytes and fibroblasts, rather than being an inducer of proliferation. Its 
release is stimulated both by autocrine and paracrine means. 
In vitro, exogenous transforming growth factor beta inhibits 
interleukin-2-dependent T cell proliferation and is itself produced by activated 
T cells (Kehrt et al, 1986). Also in vitro, it has been shown to increase the 
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expression of procollagen I. When added alone to fibroblast cultures it is 
unable to influence collagenase production, when added together with 
epidermal growth factor or" basic fibroblast growth factor, however, 
collagenase levels increase (Edwards et al, 1987). 
A single topical dose of transforming growth factor beta increases the 
synthesis of extracellular matrix and granulation tissue components as well as 
wound breaking strength in normal wounds Cromack et al, 1990). When 
applied to partial thickness porcine skin wounds, it increases connective tissue 
volume and collagen content and maturity as well as angiogenesis (Lynch et 
al, 1989). It has been shown that the inhibitory effects of interferon gamma on 
the expression of procollagen and collagen types I and III is caused by the 
inhibition of the activities of transforming growth factor beta 
(Gurujeyalakshimi and Giri, 1995). Indeed, extensive in vivo experiments 
involving the application of recombinant transforming growth factor beta and 
antibodies to it showed that the antibodies reduced the number of blood 
vessels and the content of collagen and fibronectin present in wounds (Shah et 
al, 1992). Scarring was increased in those wounds which had been treated with 
the antigen and was reduced in those treated with antibody, although tensile 
strength was not affected in either case. Transforming growth factor beta 
induces fibroblast proliferation probably via the production of platelet-derived 
growth factor and other growth factors, not directly (Rodemann and Bamberg, 
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1995), it also inhibits the synthesis of collagenase and stimulates the 
production of collagen at the mRNA level. The authors of this piece of work 
(Rodemann and Bamberg, 1995) declare that transforming growth factor beta 
is the major cytokine responsible for fibrotic deposition. 
Transforming growth factor beta mRNA expression is induced after 
wounding in adult skin, although not in foetal tissue. Foetal wounds heal 
without scarring, but if transforming growth factor beta is applied to the 
wound scar formation occurs (Lin et al, 1995). 
Transforming growth factor beta exists in three forms: termed one, two 
and three. Type 1 alone increases the production of collagen types I and III in 
cutaneous rat wounds. Type 3 alone decreases the production of collagen types 
I and III and scar formation. The neutralisation of types 1 and 2 together 
results in reduced scarring (Shah et al, 1995). Other in vivo work carried out in 
pigs, however, proved inconclusive, thus leading some to resolve that the 
exact roles of the three forms of transforming growth factor beta are still 
unclear (Levine et al, 1993). 
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1.23 Measuring cytokine production 
Technical advances have provided several analytical procedures which allow 
the investigation of cytokine presence (for review, see Carter and Swain, 
1996). Each approach has advantages and disadvantages which must be 
considered when selecting a suitable method to investigate specific activities. 
Levels of cytokines can be assessed by polymerase chain reaction 
analysis, this method is sensitive and quantitative. Whole organ homogenates 
and bulk cultures are suitable samples, but heterogeneous tissues, such as skin, 
can only provide very nonspecific data. 
Amounts of cytokines secreted into culture medium can be inferred or 
quantified by enzyme-linked immunosorbance assay (ELISA) or bioassay, 
respectively (the ELISA bioassay has the advantage of only measuring 
bioactive protein). Unfortunately, these approaches measure cytokine uptake 
and secretion together. 
A new technique developed which permits cytokine antibodies to enter 
cells and to be analysed by fluorescent antibody cell sorting (FACS) allows 
the observation of single cells producing cytokines. This allows statistical 
analysis and the observation of cells which may be producing more than one 
cytokine at a time, the expression of certain cell markers can also be localised. 
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Unfortunately, for this technique, the cells must be removed from their natural 
environment, the amount of cytokine(s) produced cannot be quantified and, 
most importantly, many cell types do not survive the necessary isolation and 
permeabilisation processes. 
In situ cytokine mRNA levels can be measured by in situ hybridisation 
and in situ cytokine protein levels can be measured by immunohistochemistry 
and immunofluorescence. In immunohistochemical analysis, cell types can be 
`identified' by nuclear counterstaining and it has the distinct advantage of 
observing the cells in their physical environment. The disadvantages include 
technical difficulty and the fact that comparisons can only be made within the 
same experiment, and it is, therefore, not the ideal technique for quantitation. 
Western blotting is a variation on the theme of immunohistochemistry. 
Antibody staining is used once the cytokine proteins have been separated by 
size with a gel. Whole organ homogenates and cell fractions work well and 
even heterogeneous tissues, such as skin, can be analysed. Unfortunately, this 
technique does not demonstrate which cells have produced the protein. 
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1.30 CELL DEATH 
1.31 Apoptosis 
Apoptosis is a fast growing area of research. The term itself is still being 
defined and redefined (Hockenbery, 1995; Kane, 1995; Schwartz and Osborne, 
1993). As a form of cell death, it has been clearly classified as distinct from 
necrosis. And as the process of apoptosis has been elucidated this distinction 
has become clearer (Majno and Joris, 1995). Indeed, light microscopy and 
straightforward histological techniques are still the most effective method of 
identification and observation of apoptotic cells (Stewart, 1994). Apoptosis is 
a form of homeostasis and maintenance not only for the immune system 
(Goldstein et al, 1991) but also for tissues such as the skin (Olson and Exerett, 
1975; Weedon et al, 1979). 
1.32 Necrosis versus apoptosis 
DNA fragmentation is among the first manifestations of the apoptotic cascade. 
Endonuclease digestion of DNA at exposed sites between nucleosomes results 
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in the liberation of fragments of 180-200 base pairs (and in multiples 
thereafter). Unfortunately, the origin of this endonuclease activity is not yet 
known. 
Grossly described, the cell condenses and fragments. The fragments 
are phagocytosed by macrophages (for review, see Goldstein et al, 1991). That 
apoptosis does not generate an inflammatory response is often part of the 
definition used to separate necrosis and apoptosis. But it is not clear how the 
phagocytes find the apoptotic cells. Apoptotic cells do not attract lymphocytes 
or neutrophils but the phagocytic macrophages do migrate (albeit a small 
distance) towards their targets. Evidence of an apparent inflammatory response 
when apoptosis occurs on a large scale has led to many workers doubting the 
definitive understanding that apoptosis means no inflammation (for review, 
see Majno and Joris, 1995). 
In cells undergoing necrosis, DNA is not cleaved into discrete 
fragments and DNA degradation actually occurs quite late in the dying 
process. Inhibition of protein or RNA synthesis does not prevent necrosis, 
which indicates that the synthesis of new molecules is not a requirement. In 
contrast to the condensation observed in apoptosis, necrotic cells swell as the 
plasma membrane is breached (Goldstein et al, 1991). 
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1.33 Apoptosis and lymphocytes 
Peripheral homeostasis of T cells is regulated by Fas (CD95) and the Fas 
ligand (FasL). Surface expression of FasL is high on activated T cells, and T 
cells can secrete soluble FasL in an autocrine and a paracrine manner, that is T 
cells can kill one another. But not all T cell death in the periphery is mediated 
by Fas and FasL: other routes involve the cytotoxic T lymphocyte associated 
molecule 4 (CTLA-4), the tumour necrosis factor receptor and perforin release 
(for review, see Kruisbeck and Amsen, 1996). There is no evidence that any of 
these methods of cell death favours a particular lymphocyte subset type, 
although there is some evidence of an association of CD4+ T cells and Fas and 
of CD8+ T cells and the tumour necrosis factor receptor (Kruisbeck and 
Amsen, 1996). Documenting the apoptosis of antigen-specific T cells is 
difficult in situ because many activated T cells home to the liver or gut for 
apoptosis. Chronic antigen exposure causes functional silencing of CD4 cells 
and eventual elimination, in CD8 cells chronic antigen exposure results in the 
downregulation of coreceptor expression and eventual elimination. 
Fas is expressed by T and B cells and other hemopoietic cells and is 
the primary mediator of cell death in CD4+ T cells, antigen-receptor binding 
activates the cell and increases Fas expression. FasL expression is of a lower 
level than that of Fas. Expression of FasL is induced on mature CD4+ and 
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CD8+ T cells following activation but is not seen on other hemopoietic cells. 
The eye and testes express FasL constantly. If activated T cells are stimulated 
by antigen, they produce interleukin 2 and then express Fas and FasL before 
dying. Fas only mediates cell death in T cells as a result of repeated antigen 
activation (for review, see Van Parijs and Abbas, 1996; Osborne, 1996). 
Cell death caused by insufficient antigenic stimulation can be 
prevented by costimulation with CD28 and by interleukin 2. In contrast, cell 
death caused by Fas and FasL linkage is actually enhanced by interleukin 2 
and is not blocked by costimulation (Lenardo, 1991). Interleukin 4 rescues 
type 2T cells from glucocorticoid-induced apoptosis, interleukin 2 rescues 
type 1T cells. The reasons for this are not known (Cory, 1995). 
1.34 Apoptosis and nonimmune cells 
As was described above, apoptosis is intimately involved in immune 
responses. Apoptosis is also vital to skin maintenance, and to skin pathologies 
because so many result through immunological mechanisms (Weedon et al, 
1979). Lichen planus is the most studied skin disease, with respect to 
apoptosis. It has been suggested that the degeneration of the epidermal cells, 
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which is characteristic of lichen planus, is due to apoptosis (Weedon et al, 
1979). 
In normal healthy skin, desquamation is the route of epidermal cell 
maintenance and keratin bodies are now recognised as being apoptosed 
keratinocytes which have dropped below the basement membrane. Enhanced 
numbers of epidermal cells undergo apoptosis following exposure to 
ultraviolet radiation (Grubauer et al, 1986). 
In cutaneous wound healing, the ultimate fate of the contractile 
myofibroblasts after their contribution to wound contraction had long been a 
mystery. It had been suspected that apoptosis was involved (Kircher, 1992). 
Desmouliere and co-workers (1995) have now confirmed that as the 
granulation tissue resolves and scar formation progresses, the decrease in the 
number of myofibroblasts present is caused by apoptosis. 
Interest in apoptosis has increased because of the overall biological 
significance of it as a phenomenon and because of the myriad of implications 
for human disease. The role of apoptosis in cancer is a major source of new 
research: most anticancer drugs induce apoptosis in sensitive cells, and it was 
recently demonstrated that the majority of tumour promoters are potent 
apoptosis inhibitors (for review, see Orrenius, 1995). 
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1.35 Apoptosis analysis , 
Because DNA cleavage during apoptosis generates characteristic fragments, 
the classical biochemical method of analysis is to use agarose gels. Necrotic 
samples produce a `smear' on the gel, apoptotic cells produce a `ladder'. This 
method, however, does not allow the in situ observation of apoptotic cells. 
Trypan blue dye uptake signifies whether the cells are viable or not but is 
unfortunately nonspecific. 
Microscopic observation of apoptosis is possible but demanding, 
evidence suggests that the apoptotic process is often complete within minutes 
and that the subsequent apoptotic body formed is visible with a light 
microscope for between 12-18 hours only. Light microscopy is the most 
straightforward method of recognising apoptotic cells in cell suspensions and 
tissue sections. And acridine orange staining gives excellent results. It 
differentially stains double stranded nucleic acids as opposed to single 
stranded nucleic acids. Denaturation of DNA is performed by hydrochloric 
acid and is then stained with acridine orange. When bound to double stranded 
nucleic acids and upon excitation with blue light, acridine orange fluoresces 
green. When bound to single stranded nucleic acids and upon excitation, it 
fluoresces red. During apoptosis, DNA is more sensitive to denaturation and 
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therefore apoptotic cells are more red than green and nonapoptotic cells are 
more green than red. 
The most accurate method of in situ histochemical detection of 
apoptosis involves the labelling of the newly exposed free ends of DNA which 
are generated during the apoptotic fragmentation process. The DNA fragments 
are labelled with dioxygenin and then bound by an antibody peroxidase 
conjugate. Staining is achieved by the addition of the relevant substrate. This 
method allows the visualisation of intact apoptotic nuclei and apoptotic bodies 





Keloids are abnormal cutaneous scars (for reviews, see Osman et al, 1978; 
Murray, 1993; McGrouther, 1994; Berman and Bieley, 1995). They are 
classically regarded as more of a cosmetic problem than a medical problem. 
Keloid lesions are indistinguishable from normally healing wounds and the 
formation of normal scars until, at some stage and via some unknown 
mechanism, excessive fibrosis develops and the scar tissue outgrows the site 
of the original injury. Hypertropic scars and keloid scars are often studied 
along side one another, but there are marked differences between the two 
conditions (for reviews, see Sahl and Clever, 1994 x2). Hypertropic scars do 
grow larger than normal scars would but, generally, they do not outgrow the 
area of the original wound site. There have been many attempts to clearly 
define the two abnormalities as distinct and to separate them clinically; it 
remains, however, that the only way to identify either one in opposition to the 
other is through histological examination (see below and, De Limpens and 
Cormane, 1982; Kischer, 1984; Kischer et al, 1990; Rudolph, 1991; 
McGrouther, 1994; Ehrlich eta!, 1994; Munro, 1995). 
There appears to be a recessive genetic predisposition to the formation 
of keloid lesions (Omo-Dare, 1975) and their formation is more common in 
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black and oriental skin than in white (Doyle-Lloyd and White, 1991). It has 
been observed, mainly by clinicians, that anatomical areas of high skin tension 
and mechanical activity, such as shoulders, form keloids more frequently than 
other areas although it is not clear why (Murray, 1993). Types of trauma 
which have been documented to induce keloid formation include the 
following: cartilage and tissue grafting (Ofodile and Wood, 1992); 
circumcision (Warwick and Dickson, 1993); dental treatment (Ow, 1989); 
Norplant insertion (Nuoro and Sweha, 1994); lightning strike (Resnik and 
Capland, 1994); hypodermic abuse (Scott eta!, 1994). 
Treatments attempted have been largely unsuccessful. The general lack 
of understanding of the processes involved in the formation and propagation 
exacerbates the problem of designing effective methods of prevention and 
therapy. Nevertheless, many attempts have been made: pressure dressings 
(Kischer et al, 1978); carbon dioxide laser (Norris, 1991); cryosurgery 
(Zouboulis et al, 1993); lasers (Alster and Williams, 1995); surgical excision 
with second intention healing (Glenn et al, 1995); X-rays (Norris, 1995); and 
steroids (Boyadjier et al, 1995). The most successful approaches to date 
involve interferon administration and silicone dressings (Berman and Duncan, 
1989; Larrabee et al, 1990; Granstein et al, 1990; Wong et al, 1995) usually 
accompanied by surgical excision. 
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A model of keloid formation has yet to be developed. Lesional 
implantation onto the backs of mice has been attempted (Shetlar et al, 1985; 
Kischer et al, 1989; Waki et al, 1991; Shetlar et al, 1991) and one report 
claiming that a small percentage of rabbits incidentally developed keloids 
following a very involved and unique protocol appeared in 1959 (Chytilova et 
aT). Unfortunately, as is the case with treatment, the development of a model is 
hampered by the lack of knowledge of keloid aetiology. 
1.41 Fibroblasts and collagen in keloids 
Fibroblasts explanted from keloid lesions have been studied extensively. The 
results of the multitude of experiments which have been carried out are 
conflicting. 
Knapp et al (1977) demonstrated that keloids contained a 
heterogeneous population of fibroblasts which produced twice the quantity of 
collagenase when compared with normal fibroblasts. In addition to this, keloid 
fibroblasts produced elevated levels of glycosaminoglycans. It was unclear, 
however, whether the population of fibroblasts producing the excessive 
collagenase were the same as those producing the glycosaminoglycans. Jutley 
et al, (1993) demonstrated that there was only a negligible difference in the 
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rate of keloid fibroblast proliferation and normal skin fibroblast proliferation. 
Two years later, Nakaoka et al (1995) presented evidence that keloid 
fibroblasts constituted a homogeneous population and that they actually 
proliferated at an elevated rate. The addition of hydrocortisone slowed the 
growth of keloid fibroblasts without any effect on collagen production (Russel 
et al, 1978; Trupin eta!, 1983). 
Work carried out on fibroblasts isolated from acne keloids by Jutley 
and co-workers (1993) was based on the assumption that keloids contain 
`normal' and `abnormal' fibroblast populations. Total collagen type I levels 
were higher than those for hypertropic scars and normal skin samples. Keloids 
and hypertropic scars also contained more collagen type III than did normal 
skin. Lee and co-workers (1992) reiterated the theory of a `manic' 
subpopulation of keloid fibroblasts over producing collagen type I with results 
illustrating higher mRNA levels of procollagen type I than normal fibroblasts 
and that the ratio of collagen types I: III was significantly elevated in keloids. 
Younai and co-workers (1994) performed a detailed study which revealed that 
keloid fibroblasts produce four times more collagen than fibroblasts grown 
from hypertropic scars and twelve times more than those from normal skin. 
Ala-Kokko. and co-workers (1987) tentatively stated in their abstract 
that `fibroblasts isolated from keloids often synthesise normal amounts of 
collagen' because they found that the collagen content of keloids was 
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approximately the same as for normal skin and that the rate of procollagen 
production by keloid fibroblasts was not significantly different from that of 
those derived from normal skin. They were tentative because, even without 
conclusive evidence, there is a central paradigm that keloid fibroblasts ̀ must' 
produce elevated quantities of collagen. This assumption is prevalent 
irrespective of the evidence. 
Friedman et al (1993) measured the transcription rates of collagen 
types I and III and found that the ratio of types I: III was very high, the reason 
being the abnormal amount of collagen type I present. The authors used the 
results to propose a mechanism for keloid growth based on the lack of 
downregulation of collagen type I production when healing had been 
completed. Abergel et al (1985*) also found the collagen types I: III ratio to be 
elevated in keloids and later found that this increase could be traced back to 
the levels of RNA (1987). Interestingly, Knapp et al (1977) only found 
collagen type I in normal skin, normal scars and keloid scars. Despite this, 
however, it is generally accepted that the ratio of collagen type I to type III is 
high in keloids. Why this should be so is not yet clear. 
Di Cesare et al (1990) documented that levels of collagen type III were 
elevated in keloids and that the collagen that was present had reduced cross- 
linking. The reduction in cross-linkage, however, was not caused by a lack of 
lysyl oxidase, the cross-linking enzyme, nor was it caused by the enzyme 
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being inactive. An earlier study (Knapp et al, 1977) had demonstrated much 
the same, with the authors reporting normal or elevated levels of lysyl oxidase 
but, again, the amount of cross-linking in keloids was reduced. 
It is not only the biochemical collagen composition of keloids which 
differs from normal samples, the histological collagen distribution is also 
altered. The collagen fibres in normal skin and normal scars lies parallel to the 
surface of the epidermis and is closely-packed. In hypertropic scars the 
collagen bundles are flatter than those in normal samples and have less 
structure although the fibres are still roughly parallel to the surface of the skin. 
The collagen fibres in keloid lesions are very disorganised, there are almost no 
discrete bundles at all, and those that are present are laid in haphazard sheets 
with random orientation and the fibres are of inconsistent lengths (for 
information on collagen fibres, see Hunter and Finlay, 1976; Ehrlich et al, 
1994; Stewart, 1995). 
Another major ultrastructural difference between hypertropic scars and 
keloids is the presence and absence of myofibroblasts, respectively. Several 
studies have been carried out to confirm the situation one way or another but 
the results were contradictory more often that they were confirmatory. James 
et al (1980) stated after the histological and microscopical analysis of one 
keloid lesion which `was found to be comprised entirely of myofibroblasts' 
that indeed the presence of these contractile cells were a component of keloid 
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formation. In 1982 Kischer et al provided evidence that both hypertropic scars 
and keloids contained myofibroblasts. Six years later (Matsuoka et al, 1988) 
histological and microscopical evidence was published that myofibroblasts 
were in fact absent from keloid lesions! Gabbiani and co-workers (1994) 
carried out electron microscopy, light microscopy and in vitro analyses on 
hypertropic scars and keloids and declared that although myofibroblasts were 
present in hypertropic scars, they were absent from keloids (Ehrlich et al, 
1994). The evidence presented thus far, therefore, has remained inconclusive. 
Considering Gabbiani's experience in the study of myofibroblasts, however, 
there is a tentative consensus that keloids do not contain myofibroblasts. 
1.42 Mast cells and histamine in keloids 
Hakanson et al (1969) and Cohen et al (1972) demonstrated higher than 
normal levels of histamine (a mast cell product) in keloid scars. Histamine is 
known to increase collagen deposition and to be a competitive inhibitor of the 
cross-linking enzyme lysyl oxidase (for review, see Smith et al, 1987). This 
evidence has lead to hypotheses that, although the enzyme is present and 
active, the increased quantity of histamine present in keloid scars is preventing 
the enzyme from performing its function. 
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1.43 The immunology of keloids 
The slow development and growth of keloids and the rapid regrowth of the 
lesion following surgical excision mimics the pattern of an immunological 
response to antigen; that is, sensitivity to antigen, memory development and 
adaptive response when reintroduced to the sensitising antigen (Kazeem, 
1988). The first evidence for an immune response being involved in keloid 
formation was presented in 1951 by Mowlem. Mowlem carried out 
histological analysis of hypertropic scars and keloid lesions and found that 
there were large numbers of lymphocytes resident in the dermis usually 
associated with hair follicles. He even went as far as to suggest that the antigen 
was present in the follicles and that it was probably keratin. 
Delayed-type hypersensitivity investigations of keloid formers has led 
to suggestions that the formation of the keloid scar is a component of an 
hypersensitivity cell-mediated immune response (for a review of the 
immunological aspects of keloid formation, see Placik and Lewis, 1992). 
Reports documenting the levels of immunoglobulin, complement and 
MHC molecules have been conflicting and generally inconclusive (see Placik 
and Lewis, 1992; Cohen et al, 1979). Increased immunoglobulin E levels do 
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appear to correlate with keloid formation, however, and these theories have 
gone even further and have suggested that mast-cell-derived products, the 
release of which is stimulated by immunoglobulin E, may play a role in keloid 
growth. 
The fact that human keloid lesions can be transplanted onto the backs 
of athymic nude mice (the execution of which was an attempt at designing a 
model), the result of which is a decrease in size suggests an autoimmune 
component. That is, without immunological stimulation the keloid does not 
grow. Interestingly, transplantation of keloid lesions between human subjects 
and even in different anatomical areas of the same patient were unsuccessful, 
the tissues were not tolerated (Calnan and Copenhagen, 1967). 
Mowlem is not the only researcher to nominate an antigen. Suggested 
antigens for this immunological response have included melanin and collagen 
(Oluwasanmi, 1974) and sebum (Yagi et al, 1979; Fasika, 1992). Despite 
many attempts, however, neither the nature, the identity nor the origin have 
been elaborated. And, as yet, there has been no large-scale study to ascertain if 
keloid formers have any systemic dysfunction in their immune responses or 
not. 
Keloids can take years to grow and the same patients are able to form 
them in different areas on their bodies, but there are no confirmed reports of 
full-body, systemic reactions characteristic of an autoimmune response (it is 
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known that systemic lupus erythematosus (SLE) is more common in black 
people than in white people and in women more than men; keloids are also 
more common in black skin than white and in women than men but this 
phenomenon has generally been explained by the higher number of women 
having their ears pierced, a situation which is less definitive in the present day. 
Is it possible that the positive correlation of females and keloid formation has a 
less obvious association? ). 
1.44 Cytokines and keloids 
Tritiated thymidine experiments adding a variety of cytokines to the culture 
media sustaining keloid fibroblasts have shown that they reacted as normal 
fibroblasts to platelet-derived growth factor, transforming growth factor beta 
1, interferon gamma and histamine. But when epidermal growth factor was 
added, the level of thymidine incorporation was enhanced (Kikuchi et al, 
1995). The keloid fibroblasts in this study produced 4.4 times more collagen 
than normal fibroblasts. When interferon gamma was added, the production of 
collagen type I was decreased in both normal and keloid fibroblasts with the 
difference being more marked in keloids. Transforming growth factor beta 1 
increased the production of collagen type I by both cell types. And histamine 
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increased the production of collagen type I in keloid fibroblasts only. The 
addition of transforming growth factor beta inhibited the epidermal-growth 
factor-stimulated growth of normal fibroblasts and fibroblasts from normal 
scars, but actually increased the growth of fibroblasts explanted from keloids 
under the same conditions. Tan et al (1993*) reported decreased collagen type 
I gene expression in keloid fibroblasts in response to basic fibroblast growth 
factor. Babu et al (1992) claimed that total protein synthesis by normal dermal 
fibroblasts increased in response to transforming growth factor beta 1 but had 
no effect on keloid fibroblasts. 
Fibroblasts taken from the expanding edge of the keloid lesion actively 
express collagen type I genes at a much higher level than they do type III, and 
the presence of transforming growth factor beta 1 is associated with areas of 
active collagen type I production (Peltonen et al, 1991). The authors of this 
work suggested that endothelial cells in the area of the keloid lesion expansion 
were producing transforming growth factor beta 1 which stimulated the 
autocrine production of more transforming growth factor beta 1 which, in turn, 
stimulated the fibroblasts to produce excessive collagen type I. Haisa et al 
(1994) reported that keloid fibroblasts were more chemotactically and 
mitogenically responsive to platelet-derived growth factor than were normal 
fibroblasts. And that there was no difference in response between the two cell 
types when epidermal growth factor or fibroblast growth factor were added. 
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The enhanced response of keloid fibroblasts to platelet-derived growth factor 
was mediated by increased levels of receptors (almost four or five times more 
compared with normal fibroblasts). 
Another report demonstrated that keloid fibroblasts produced twelve 
times more collagen than hypertropic scar and normal fibroblasts. And that the 
administration of transforming growth factor beta increased the level 2.7-fold 
in keloid fibroblasts without having any effect on hypertropic scar or normal 
fibroblasts. The addition of neutralising antibodies to transforming growth 
factor beta decreased the rate of collagen synthesis by keloid fibroblasts by 




It seems that the phenomenon of keloids is best regarded as a problem waiting 
to be solved. Evidence provided by many studies carried out over many years 
reveals who is more likely to develop keloids and what the clinical outcome 
will be. There is no evidence of a systemic abnormality in the characteristics 
of keloid patient fibroblasts nor in their wound healing ability. But there is a 
local malfunction which results in excessive collagen deposition. Much more 
work needs to be carried out on the identification of molecules and mediators 
present within the keloid and the wound bed which preceded it. It is rather 
unethical, however, to biopsy patients throughout the healing process whether 
or not it were possible to guarantee that a keloid would result. And the lack of 
understanding of keloid aetiology has thus far prevented the development of 




Ultimately, the work in this thesis is aimed at `mapping' keloid scar samples. 
The first step in this objective is to attempt to identify the cell types present 
within the lesion and the accompanying dermis through the 
immunolocalisation of CD cell surface markers. Once it has become possible 
to suggest the composition of the tissues, it is feasible to locate mediators 
within the samples and speculate on their roles in keloid formation and 
propagation. 
It is hoped that by the end of the work it will be possible to identify a 
mediator (or a group of mediators) which is a viable culprit for the 
orchestration of keloid formation. The candidates selected to identify cells 
within the tissues are as follows: CD4, CD8, CD30, CD31, CD58; and those 
mediators selected to study the development and propagation of keloids are 
interferon gamma, interleukins 2,4 and 10, epidermal growth factor, platelet- 
derived growth factor, basic fibroblast growth factor, vascular endothelial 
growth factor and transforming growth factor beta. 
Previous work has demonstrated that the administration of interferon 
gamma has a therapeutic influence on both keloid lesions and hypertropic 
scars. And that neutralising the activity of vascular endothelial growth factor 
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inhibits the growth of tumours. Also to be included in this thesis, are 
investigations of the effect of neutralising the action of interferon gamma on 
the production of hydroxyproline and glycosaminoglycans in a model 
featuring a granulation tissue component and, using the same model, the effect 
of neutralising the action of vascular endothelial growth factor on the 
development of new blood vessels. It is hoped that evidence obtained from 
these studies will permit the proposal of a mechanism responsible for the 
beneficial effect of the administration of interferon gamma to keloid lesions 
and whether or not the inhibition of new blood vessel formation could allow 
the regulation or prevention of keloid growth. 
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Tuck Original (TO) mice were used throughout. 
2.12 Chemicals 
Any inorganic chemicals used to prepare buffers and solutions were purchased 
from Merck Ltd (Analar grade). Industrial methylated spirit (IMS) and all stains 
and dyes were also supplied by Merck Ltd. 
2.13 Antibodies 
bFGF (polyclonal rabbit antibovine) 
Biotinylated secondary antibodies 
EGF (polyclonal rabbit antimurine) 
PDGF (polyclonal goat antihuman) 
TGF-ß (polyclonal chicken antiporcine) 
Vectastain elite ABC kit 
IFN-y (monoclonal hamster antimurine) 
British Biotechnology Ltd 
Vector Laboratories 
Genzyme 
British Biotechnology Ltd 





CD markers (monoclonal mouse antihuman) Serotec 
IL-2,4,10 (polyclonal goat antihuman) R and D Systems 
CD30 marker (monoclonal mouse antihuman) Serotec 
IL-2 (monoclonal rat antimurine) Genzyme 
IFN-y (polyclonal goat antihuman) R and D Systems 
EGF, PDGF, bFGF, TGF-ß R and D Systems 
(polyclonal goat antihuman) 
VEGF (polyclonal rabbit antihuman) Oncogene Science 
2.14 Antigens 
VEGF (recombinant human) R and D Systems 
bFGF, EGF, PDGF, TGF-ß (recombinant human) Calbiochem 
IL-2,4,10 (recombinant murine) Genzyme 
IL-2,4,10 (recombinant human) PeproTech 
IFN-y (recombinant human) PeproTech 




Other biochemical reagents were purchased from Sigma with the exception of 
the following: 
Mycobacterium tuberculosis (stains C, DT, PN) Central Veterinary Supplies 
2.16 Human tissues 
Clinical samples were collected from consenting patients being treated at St 
Bartholomew's and Middlesex Hospitals. The collection of keloid tissues 
consisted of 111 samples (n = 111); 52% of which were taken from female 
patients; 70% of which were black skin samples, 20% of which were oriental or 
asian samples and 10% of which were white samples (approximately). Patient 
history was unknown as was anatomical area any treatment administered was 
also unknown. The collection of normal tissues used in these studies consisted of 
15 samples (n = 15) and was taken from a variety of anatomical areas, from both 
sexes and from a variety of skin colours. Normal tissues were mainly removed 




2.20 HOUSING AND HUSBANDRY 
Female Tuck Original (TO) mice were used throughout (25-30g). Ten animals 
were housed in each cage. Cages were plastic and lined with sawdust, SDS 
pellets and water were provided without restriction. Environmental conditions 
such as humidity, light and temperature were controlled and maintained. 
2.30 MURINE AIR POUCH MODEL 
The discussion section included in Chapter 3 explains the benefits of the use of 
this model for work of the type included in this thesis. 
231 Formation of pouch 
On day 0,3m1 air was injected into the dorsal subcutaneous tissue to form a 
pouch. Twenty-four hours later, 0.5m1 0.1% volume/volume croton oil in 
Freund's complete adjuvant (5mg/ml Mycobacterium tuberculosis [strains C, DT 
and PN] in Freund's incomplete adjuvant) was injected into the inflated pouch. 
Animals were allowed to recover and then sacrificed at 3,7,14,21 or 28 days by 
carbon dioxide inhalation. 
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2.32 Removal of experimental tissue 
The fur on the back of the animal was shaved and the whole pouch carefully 
dissected, any inflammatory exudate was removed. The upper portion of the 
pouch was excised and prepared for histological study (2.80) and the lower 
portion for biochemical analysis (2.70), or the whole pouch was recovered and 
prepared for dry weight investigation (dried in oven for 2 days at 56°C). 
2.40 INVESTIGATING MURINE AIR POUCH VASCULARITY (Kimura 
eta!, 1985) 
2.41 Tissue digestion 
The whole pouch was carefully dissected from the animal and placed in 
digestion buffer (12 units/ml papain, 1mM ethylenediaminotetracetic acid 
[EDTA] in 0.05M phosphate buffer [containing KCl and KH2P04] pH7.0) at 
5 6°C for 2 days (I ml aliquots were used in assays). 
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2.42 Formation of vascular cast (Modified from Kimura et al, 1986) 
Animals with a7 day air pouch (2.30) were anaesthetised with 0.5m1 
Hypnorm/Hypnovel intraperitoneally (1 part Hypnorm, 1 part Hypnovel, 2 parts 
water). lml 3% carmine solution (10% carmine dye, 5% gelatine) was injected 
into the tail vein and the carcasses chilled to solidify the gelatine. The pouch was 
then recovered and digested (2.41), iml 5M sodium hydroxide was added to 
solubilise the dye and the samples then diluted 1: 20 with 5M sodium hydroxide. 
Particulates were removed using 0.22µm Whatman filters and 200µm of each 
sample placed in a 96-well plate. The amount of carmine present was measured 
using a Biotek (model ED 10) microplate reader at 490nm. 
2.43 Air pouch clearing 
Animals with a7 day air pouch were injected with carmine (2.42), the dorsal fur 
was shaved and the top area of the pouch excised. Tissues were washed in Hanks 
buffered saline solution and immersed in 10% formal saline (4% formaldehyde 
in 0.9% aqueous sodium chloride) for 2 days. The tissues were then dehydrated 




2.50 INVESTIGATING MURINE AIR POUCH TISSUE 
GLYCOSAMINOGLYCAN (GAG) CONTENT 
A standard curve was constructed using chondroitin sulphate with digestion 
buffer (2.41) as diluent. 10µ1 aliquots of digested samples (2.41) were mixed 
with 200µl DMB solution (16mg 1,9-dimethylmethylene blue chloride in 5m1 
IMS and 95m1 formate buffer, 2g sodium formate, 19m190% formic acid made 
to 1 litre using distilled water) in wells of a 96-well plate. The plates were 
allowed to stand for 1 minute and absorbance read using a Biotek (Model 
ED 10) microplate reader at 53 5nm. 
2.60 INVESTIGATING MURINE AIR POUCH TISSUE 
HYDROXYPROLINE (HPr) CONTENT (Woessner, 1961) 
A standard curve was constructed using hydroxyproline diluent (IOml 4M 
sodium hydroxide with 10ml 0.47M citric acid). Digested samples (2.41) were 
centrifuged at 700g for 10 minutes and l00µ1 aliquots evaporated overnight at 
80-100°C. Samples were reconstituted using l00µ1 4M sodium hydroxide and 
agitated until mixed. Samples were incubated at 120°C for 3 hours and 
evaporated overnight then reconstituted with 100µl 4M sodium hydroxide and 
100µ10.47M citric acid. 25µ1 of each sample were placed into the wells of a 96- 
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well plate and 125µl of chloramine T added (0.14g chloramine T, lml propan-2- 
ol, 1ml distilled water, 8m1 citrate buffer: 1Og citric acid monohydrate, 14.5g 
anhydrous sodium acetate, 6.8g sodium hydroxide in 150m1 water. 2.4m1 glacial 
acetic acid was added. pH adjusted to 6.0 and solution made to 200ml. Stored 
under toluene at 4°C) before a 20 minute incubation at room temperature. 125µ1 
DMAB/perchloric acid solution was added (1.7g dimethylaminobenzaldehyde 
[DMAB] was dissolved in 7m1 propan-2-ol. 3m160% perchloric acid added and 
the solution maintained at 65°C to prevent precipitation) followed by a 15 
minute incubation at 65°C. Absorbance was read using a Biotek (Model ED 10) 
microplate reader at 560nm.. 
2.70 BIOCHEMICAL ANALYSIS: WESTERN BLOTTING 
The rationale for using this method of biochemical analysis are outlined in 
Chapter 1. 
2.71 Sample preparation 
Air pouch tissues (2.30) were dissected and the lower part homogenised in lml 
of 1mM phenylmethylsulphonyl fluoride, 70mg/ml pepstatin A, 0.01% leupeptin 
(weight/volume) in 50mM Tris (6.06g Tris HCl and 1.39g Tris Base in 1 litre of 
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water), pH 7.4 before lml gel loading buffer was added (50mM Tris HC1,10% 
SDS, 10% glycerol, 10% 2-mercaptoethanol, 2 mg/ml bromophenol blue) and 
the samples boiled for 3 minutes. The samples were centrifuged at 10 000g for 
10 minutes and the protein content calculated, see below. 
2.72 Assay to measure protein content of air pouch samples (Bradford, 1976) 
A standard curve was constructed using bovine serum albumin (BSA) and 
sample homogenising buffer (2.71). 10µl of each sample was placed in the wells 
of a 96-well plate and 2O0µ1 Bio-Rad Protein Assay Dye Reagent added (made 
up according to instructions). Absorbance was measured at 595nm using a 
Biotek (Model EL310) microplate reader. Results are expressed as mg/ml of 
protein. 
2.73 Electrophoresis of air pouch samples 
Electrophoresis was executed as instructed using the Bio-Rad Mini-Protean II 
Electrophoresis Cell on a 15% discontinuous (Laemmli) polyacrylamide gel. 
Combs used were 0.75mm thick and contained ten 36µl wells. Equivalent 
quantities of protein (2Oµ1,1mg/ml concentration) were loaded into each well to 
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allow comparison of samples. Gels were run at 90V for 5 minutes and then at 
180V for 45 minutes, or until the dye front had reached the base of the gel. 
2.74 Transfer of proteins from gels 
Transfer was executed as instructed using the Bio-Rad Mini Trans-Blot 
Electrophoretic Transfer Cell. Blotting media used was 0.45µm nitrocellulose 
membrane. Transfers were run at 100V for 1 hour. 
2.75 Immunoblot detection of transferred VEGF antigen 
The nitrocellulose membrane containing the transferred antigens was incubated 
overnight in 5% dried nonfat milk in TBS (200mM Tris HCI, 500mM sodium 
chloride, pH7.5) to block free protein binding sites. Membranes were washed in 
TTBS (TBS with 0.05% Tween-20) with gentle agitation, for 5 minutes, 3 times 
before incubation with the primary antibody diluted in TBS to the optimum 
concentration (x500) and refrigerated overnight. The membranes were washed 
as before and biotinylated secondary antibody applied (diluted 1: 200 in TBS). 
Two hours later, the wash step was repeated and the streptavidin-biotinylated 
alkaline phosphatase solution applied (diluted 1: 200 in TBS) for a further 2 
hours. Following incubation with the alkaline phosphatase complex, membranes 
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were washed thoroughly in TTBS (15 minutes, 3 times). The substrate 5-bromo- 
4-chloro-3-indolyl phosphate/nitroblue tetrazolium (BCIP/NBT) was prepared 
according to instructions and applied for 10-30 minutes, or until colour 
development was complete. The development reaction was stopped using 
distilled water. 
2.80 HISTOLOGICAL ANALYSIS 
2.81 Tissue preparation 
Icm2 pieces of tissue taken from the upper most part of the air pouch (2.30), or 
from human samples, were frozen in n-hexane (precooled in liquid nitrogen) and 
stored under liquid nitrogen until use. 
2.82 Wax embedding 
1cm2 pieces of tissue taken from the upper most part of the air pouch (2.30), or 
from human samples, were fixed in 10% formal saline for 48 hours. The tissues 
were rinsed in 70% aqueous alcohol and then emmersed in 70% aqueous, 90% 
aqueous and 100% pure alcohol for 24 hours each and two changes of toluene 
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for 48 hours each. Wax embedding was carried out at 56%. Tissues were 
sectioned at 4µm on a base-sledge microtome (Leitz). 
2.83 Cryotomy 
Tissues were attached to brass cryostat chucks using OCT chilled in dry ice. 
Chucks were then mounted in a Bright Cryostat (Model 5030), cooled before use 
to -25°C. 71im sections were cut, thaw-mounted onto TESPA (3- 
aminopropyltriethoxy silane)-coated 4-spot PTFE slides (5 minutes in acetone, 5 
minutes in 4% TESPA in acetone and air dried) and stored at -20°C until use. 
2.84 Fixation (Bancroft and Stevens, 1982) 
Sections were fixed in 4% paraformaldehyde (prepared by heating 8% aqueous 
paraformaldehyde solution to 60°C, concentrated sodium hydroxide was added 
until the solution cleared. The mixture was allowed to cool and an equal volume 




2.85 Histological stains 
Van Gieson's 
Sections were stained with celestine blue for up to 15 minutes, or until nuclei 
were intensely stained, and washed in tap water. This was followed by 5 minutes 
in Mayer's haematoxylin and a tap water wash. Slides were then rinsed in 
distilled water before being stained for 2 minutes with Van Gieson's solution and 
rinsed again. Tissues were dehydrated using ascending concentrations of 
alcohol, cleared in xylene and mounted using DPX. 
Stains mature collagen fibres deep red, muscle and fibrin yellow and nuclei 
black. 
Haematoxylin and eosin 
Sections were stained with Harris's haematoxylin for 5 minutes and washed with 
distilled water. Staining was differentiated using acid/alcohol (70% aqueous 
alcohol, 1% concentrated hydrochloric acid) and the slides washed in tap water 
until a blue colour developed. Sections were stained with 1% aqueous eosin Y 
for 1 minute and then washed for 5 minutes in tap water. Tissues were 
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dehydrated using ascending concentrations of alcohol, cleared in xylene and 
mounted using DPX. 
Stains nuclei blue, extracellular matrix components and cytoplasm various 
shades of pink. 
Toluidine blue 
Unfixed sections were dipped in toluidine blue (0.25%) in veronal acetate buffer 
(O. 1M pH4.5) for 10 seconds. Sections were then washed in distilled water, 
dehydrated and mounted. 
Stains glycosaminoglycans purple, nuclei and other cell components blue and 
mast cell granules pink. 
Acridine orange 
Unfixed sections were immersed in one part acridine orange (0.1%) in distilled 
water, nine parts Krebs-Ringer solution (pH6.2) for approximately 15 minutes. 




Fluorescent staining of nuclei and fibrous tissue green, nucleoli and cytoplasmic 
nucleic acids red. Black background. 
2.90 IMMUNOHISTOLOGIAL ANALYSIS 
Immunocytochemistry (the use of labelled antibodies as specific reagents for 
the localisation of antigens in situ) was extensively used in the research for 
this thesis because it allows the visualisation of cells and mediators in situ. 
That is, one aim of the work in this thesis was to identify cells within the 
tissue samples and any mediators present as well as their location. It was 
hoped that this evidence could be used to speculate on the possible 
mechanisms of keloid formation and propagation. 







Sections were fixed in acetone for 10 minutes and allowed to air dry before use. 
2.94 Immunohistological staining 
Following rehydration of the tissues in 10mM phosphate buffered saline pH 7.4 
([PBS] 80g NaCl, 2g KCI, 11.5g Na2BPO4,2g KH2PO4 in 10 litres of water), 
endogenous peroxidases were quenched (0.3% hydrogen peroxide in methanol) 
for 30 minutes and the sections washed for 5 minutes, 3 times in PBS. The 
appropriate serum (diluted 1: 200 in 0.1% essentially globulin free BSA in PBS) 
was used to block nonspecific binding of immunoglobulin G for 30 minutes. 
Primary antibody diluted to optimum concentration (in 0.1% sodium azide, 
0.1% Triton X100,0.01% BSA in PBS) was applied and the sections incubated 
at 4°C overnight. Sections were then washed for 5 minutes, twice in PBS 
containing 0.1% Triton X100 and once in PBS before being incubated for a 
further 30 minutes in a biotinylated secondary antibody diluted 1: 200 in PBS 
containing 1.5% normal serum. Following incubation with the secondary 
antibody, sections were washed for 5 minutes, twice in PBS containing 0.1% 
Triton X100, once in PBS and incubated for 30 minutes with Vectastain ABC 
horseradish peroxidase (made up according to instructions in 5m1 PBS 
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containing 0.5M sodium chloride). Unbound complex was removed by washing 
for 5 minutes, 3 times in PBS and then 5 minutes in 0.05M Tris HCl pH7.6. The 
substrate, 3,3'-diaminobenzidine tetrahydrochloride (DAB) was prepared 
according to instructions (10mg DAB in 20m1 0.05M Tris HCI pH7.6 with 3.4 
weight/volume hydrogen peroxide) and applied for 1-5 minutes, until colour 
development was complete. The development reaction was stopped using water. 
Tissues were counterstained using Mayers haematoxylin, washed in tap water, 
differentiated using acid/alcohol (70% aqueous alcohol, 1% concentrated 
hydrochloric acid), dehydrated in ascending concentrations of alcohol, cleared in 
xylene and mounted using DPX. 
2.100 IN SITU END LABELLING 







Sections were fixed in 10% buffered formalin for 10 minutes, post-fixed in 
ethanol: acetic acid (2: 1) for 5 minutes at -20°C and used immediately. 
2.104 In situ end labelling 
In situ end labelling was carried out as instructed using the ApopTag In Situ End 
Apoptosis Detection Kit - Peroxidase. Sections were counterstained using 
Mayer's haematoxylin. 
2.110 STATISTICS 
A statistics package for social sciences was used in the analysis of in vivo 
experimental data. Statistical significance calculated using the Mann-Whitney 
U-test. The Mann-Whitney test is a nonparametric statistical test which 
identifies differences between two conditions of one independent variable 
(Hinton, 1995). 
Quantitative data collected from immunohistochemical analysis were 
analysed without the aid of a computer package (Rowntree, 1991; Bland, 1996); 
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the statistical significance was determined using the Mann-Whitney test. Results 
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Because the profile of normal wound resolution in the murine air pouch model 
is to be used to illustrate the changes in vascularity and glycosaminoglycan 
and hydroxyproline content in a `normal' response, as well as for comparison 
with the abnormal human keloid tissues, it is necessary to describe aspects of 
the model in detail. Such aspects include the appearance and behaviour of 
various cell types, cytokine involvement, vascularity development and 
glycosaminoglycan and hydroxyproline distribution. This chapter aims to 
describe the tissues and to establish those facts which will aid the 
interpretation of the results of subsequent experiments. 
3.11 The normal murine air pouch model timecourse 
This model was originally developed to study the role of angiogenesis in 
granulation tissue formation and resolution (Kimura et al, 1985). Since then it 
has been used to study many processes including granulation tissue 
contraction (Appleton et al, 1992) and the effects of transforming growth 
factor beta on matrix deposition (Appleton et al, unpublished data). It is an 
immune driven model and has a strong T cell component. A study by 
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Appleton and co-workers (1993) on the spatial and temporal distribution of 
cytokines throughout the timecourse furthered the understanding of the roles 
of these mediators in granulation tissue formation and wound resolution. 
The execution of the murine air pouch model was described in Chapter 2. The 
tissue dry weight, carmine content and vascularity are displayed in Figures 
3.1,3.2 and 3.3 (Appleton et al, 1993). 
Tissue dry weight (mg) 
Granulation tissue dry weight was 47.7 t 3.8mg at day 3 and rose to a peak at 
day 7 (120.9 ± 4.4mg), tissue was harvested at this timepoint and used for the 
subsequent vascularity experiments. Following day 7 the granulation tissue 
dry weight fell gradually to 51.4: h 3.4mg at day 28 (Figure 3.1). 
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Carmine content (mg) 
Carmine content at day 3 was 0.45 ± 0.21 mg. The peak of carmine content 
occurred at day 5 (0.99 ± 0.06mg) and then fell steadily to day 28 (0.43 f 
0.02mg; Figure 3.2). 
Vascularity (ice) 
Vascularity of air pouch tissues also peaked at day 5 (14.84 ± 0.5pg/mg) after 
a level at day 3 of 9.59 f 0.33µg/mg. The vascularity fell sharply at day 7 
(8-14: 1: 0.2µg/mg) and wavered thereafter through to day 28 (8.34: k 0.2µg/mg; 
Figure 3.3). 
Figures 3.4,3.5,3.6 illustrate the histology of the murine air pouch at days 3, 
7 and 28, respectively. 
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Day 3 histology 
At day 3 the murine air pouch tissues displayed large concentrations of 
inflammatory cells which were predominantly polymorphonuclear neutrophils 
but also included macrophages, fibroblasts and some lymphocytes. Blood 
supply to the granulation tissue was provided by capillaries which were 
probably derived from existing vessels and were seen mainly in the area of 
granulation tissue just beneath the skeletal muscle layer. The extracellular 
matrix displayed a small quantity of collagen fibres in the area of granulation 
tissue close to the skeletal muscle layer. Mast cells were present in the dermis, 
some were degranulated, although very few were seen in the granulation tissue 
(Appleton et al, 1993; Figure 3.4). 
Day 7 histology 
Maximum tissue dry weight occurred day 7 (this was evident by the increase 
in depth of tissue). The granulomatous/granulation tissue itself was 
heterogeneous in terms of cell type distribution throughout the depth of the 
tissue. The area bordered by the skeletal muscle featured a loosely packed 
matrix embedded with fibroblasts and macrophages, blood vessels were sparse 
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compared with the neighbouring granulomatous/granulation tissue region, the 
cellular nature of which was approximately the same as that of day 3 
(Appleton et al, 1993; Figure 3.5). 
Day 14 histology 
At day 14, individual regions in the granulation tissue were more pronounced. 
The region below the skeletal muscle layer featured a more densely packed 
matrix and increased numbers of embedded fibroblasts; some macrophages 
and lymphocytes were also present. The blood vessels were more prominent 
than at day 3 and the neighbouring granulation tissue region was similar in 
appearance to that of day 7. The area of granulation tissue bordering the pouch 
cavity appeared to be approximately the same in nature as that of day 3 
(Appleton et al, 1993). 
Day 21 histology 
At day 21 different regions were evident in the granulation tissue layer, with 
the area below the skeletal muscle featuring a fibrotic extracellular matrix 
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containing numerous blood vessels, although the area was not densely packed 
there were many fibroblasts and increased numbers of mast cells. The amount 
of collagen had increased and there were many fibroblasts and some 
macrophages and lymphocytes. The tissue region close to the pouch interface 
resembled that of day 3 (Appleton et al, 1993). 
Day 28 histology 
By day 28 the granulation tissue area below the skeletal muscle layer had 
increased in depth and mature blood vessels were evident. The number of mast 
cells throughout the granulation tissue had decreased and collagen fibres 




Figure 3.1 A graph to show the total dry weight (mg) of murine air pouch 
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Figure 3.2 A graph to show the total carmine content (mg) in murine air 
pouch tissue samples taken throughout the timecourse of 3-28 days 
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Figure 3.3 A graph to show the ratio of carmine , up) to tissue dry weight (mg) 
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Figure 3.4 A micrograph to illustrate the histology of murine air pouch tissue 
sampled at day 3 of the timecourse (magnification x20, representative of 
n=12) 






Figure 3.5 A micrograph to illustrate the histology of murine air pouch tissue 




Figure 3.6 A micrograph to illustrate the histology of murine air pouch tissue 




3.12 CD4 and CD8 markers in murine air pouch tissues 
The cell surface marker CD4 is involved in the recognition by T cells of 
foreign antigens in association with MHC class II molecules. The 
administration of CD4 antibodies inhibits the functions of T cells in vivo and 
in vitro (Barclay, 1994). CD4 is expressed by those peripheral blood T cells 
which are CD8 negative (approximately two thirds of the total). 
CD8 is involved as a co-receptor with those T cell receptors restricted 
to MHC class I molecules in the recognition of foreign antigens. It is 
expressed by those peripheral blood T cells which are CD4 negative 
(approximately one third of the total). 
Studies of normal murine skin samples (see Table 3.1) showed that 
almost one half of the dermal hair follicles contained some CD4+ T cells. By 
day 3 there were numerous cells in the dermis (more than CD8+ T cells) and 
throughout the granulomatous/granulation tissue. A general increase in the 
number of CD4+ T cells was evident at day 7, and remained consistent through 
day 14 (Figure 3.7). By day 21, CD4+ T cells numbers had decreased in the 
dermis but had increased in the granulomatous/granulation tissue, particularly 
around the lower area of the tissue close to the pouch. CD4+ T cells were 
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fewer in number in the granulomatous/granulation tissue by day 28, and were 
approximately equivalent to the pattern seen at day 3. 
Figures 3.7 and 3.8 illustrate the distribution of CD4 and CD8 lymphocyte 
markers at day 14, respectively. 
Figure 3.7 A micrograph to illustrate the immunolocalisation of the CD4 cell 
surface marker in a day 14 murine air pouch tissue (magnification x50; 
dilution 1: 50; representative of n=12) 
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Figure 3.8 A micrograph to illustrate the immunolocalisation of the cell 
surface marker CD8 in a day 14 murine air pouch tissue (magnification x50; 
dilution 1: 50; representative of n=12) 
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Control murine skin samples displayed isolated single CD8+ T cells in dermal 
hair follicles, although the numbers were almost negligible. By day 3 there had 
been a small increase in numbers of CD8+ T cells in the dermis and there were 
now some present in the granulomatous/granulation tissue. By day 7 there 
were more CD8+ T cells in the granulomatous/granulation tissue, in the area 
close to the pouch cavity, and some in the dermis, a pattern which was 
consistent through to day 14 (Figure 3.8). At day 21 less immunolabelled 
CD8+ T cells were seen in the dermis; numbers in the 
granulomatous/granulation tissue were approximately the same as for day 14. 
The number of CD8+ T cells present at day 28 was more than that seen at day 
3 but was less than that at day 7, and the distribution was more diffuse. 
Table 3.1: Quantitative data for the immunolocalisation of cell surface 
markers CD4 and CD8 in the murine air pouch timecourse. Results are 
expressed as the mean and standard error (f) of positively stained cells in n= 
4 tissues, 10 fields of view per tissue (4mm2, x20). The Mann-Whitney U-test 
was used to investigate statistical significance (P < 0.05 = *), groups were 
compared with day 3 data 
Day Region CD4 CD8 
3 D 49.0±2.9 4.0±0.8 
3 GT 29.8±3.6 6.8±1.0 
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7 D 28.0±1.4* 7.0±1.8 
7 GT 65.8±4.1* 32.3±2.5* 
14 D 29.5±2.4* 15.3±2.5* 
14 GT 106.0±5.9* 39.0±5.5* 
21 D 21.5±2.1 * 6.3±1.5 
21 GT 134.0±6.7* 38.8±3.9* 
28 D 50.5±6.0 5.8±2.2 
28 GT 30.0±5.7 14.8±3.1 * 
(U, dermis; UT, granulatioNgranutomatous tissue) 
3.13 Human tissues 
The accessory structures of the skin, such as hair follicles, sebaceous glands, 
sweat glands and hairs, mainly lie in the dermis (Figure 3.10). 
B cells are rarely found in normal control skin samples, whereas T cells 
(normally T helper cells) are present in the dermis usually associated with hair 
follicles, sebaceous glands, sweat glands or blood vessels and the epidermis. 
Generally, ̀ free' lymphocytes are not seen. Small numbers of macrophages are 
present, and are spread diffusely (Martin and Muir, 1990). Dendritic epidermal 
T cells found in association with keratinocytes of the epidermis express the y/S 
antigen receptor (Havran et al, 1991). 
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Figures 3.9 and 3.10 represent sections through normal human tissue sampled 
from the chest area of a caucasian patient. 
Figure 3.11 represents a cross-section though a typical keloid sample taken 
from the face of a black patient. 
Figure 3.9 A micrograph to illustrate the histology of normal human skin 
(magnification x20, representative of n=15) 
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Figure 3.10 A micrograph to illustrate the histology of normal human skin 
(magnification x20, representative of n=15) 
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Figure 3.11 A micrograph to illustrate the histology of human keloid tissue 
(magnification x20, representative of n=55), the arrows point out populations 
of lymphocytes. Note the numerous lymphocytes in focal aggregates and the 
excessive collagen deposition in the dermis 
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Two very important differences between normal skin samples and keloid 
tissues are clear in Figures 3.9,3.10 and 3.11: numerous pockets of 
lymphocytes in the upper dermis and areas stained intensely for collagen in the 
keloid. 
Martin and Muir (1990) performed an extensive investigation of lymphocytes 
in normal skin, wounded tissues, hypertropic scars and keloid samples. They 
documented no B cells and increased numbers of T helper lymphocytes. Also 
consistent with observations made during the research for this thesis was their 
description that lymphocytes were concentrated around hair follicles and the 
invading edge of the keloid lesion. In addition, they introduced valuable 
evidence that the lymphocyte presence was consistently intense whatever the 
age of the keloid scars. 
3.14 CD58 marker in human keloid tissues 
The cell surface marker CD58 is strongly expressed on macrophages and 
associates with CD2 in order to enhance antigen-specific T cell activation. 
That is, CD2 and CD58 form an adhesive pair between T cells and antigen- 
presenting cells in order to induce a response to antigen. 
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Using CD58, the pattern of macrophage presence in keloid tissues was shown 
to be an even distribution of isolated cells throughout the dermis and 
numerous cells `buried' in masses of lymphocytes in the dermis. Virtually no 
CD58 immunolabelling was present in the keloid lesion itself (see Figures 
3.12,3.13 and Table 3.2). 
Figure 3.12 A micrograph to illustrate the immunolocalisation of the cell 
surface marker CD58 in human keloid tissue (magnification x100; dilution 
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Figure 3.13 A micrograph to illustrate the immunolocalisation of the cell 
surface marker CD58 in human keloid tissue at higher power (magnification 
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3.15 CD31 marker in human keloid tissues 
The cell surface marker CD31 (also known as PECAM, platelet endothelial 
cell adhesion molecule 1) is highly expressed on endothelial cells and is 
concentrated at the junction between them. It is present on platelets and some 
macrophages (Barclay, 1994). 
Figure 3.14 shows intense immunolabelling for CD31 in endothelial cells (or 
the junctions between them) in blood vessels in the keloid lesion, very few 
isolated cells are stained (that is, cells which are unlikely to be endothelial 
cells and which are possibly macrophages) which is consistent with the lack of 
CD58 immunolabelling in the lesion (see Figures 3.12,3.13 and Table 3.2). 
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Figure 3.14 A micrograph to illustrate the immunolocalisation of the cell 
surface marker CD31 in human keloid tissue (magnification x100; dilution 

















3.16 CD4 and CD8 markers in human keloid tissue 
Figures 3.15 and 3.16 represent CD4+ and CD8+ immunolocalisation in a 
keloid sample. The number of CD4+ T cells in the dermis present is striking, 
as is the number of CD8+ T cells. In addition to the CD4+ T cell aggregations 
of lymphocytes in the keloid dermis, small groups of lymphocytes (and 
sometimes single lymphocytes) were present throughout the samples (see 
Table 3.2). 
Figure 3.15 A micrograph to illustrate the immunolocalisation of the cell 
surface marker CD4 in human keloid tissue (magnification x50, dilution 1: 50, 
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Figure 3.16 A micrograph to illustrate the immunolocalisation of the cell 
surface marker CD8 in human keloid tissue (magnification x50, dilution 1.50, 
representative of n= 75) 
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3.17 CD30 marker in human keloid tissues 
The function of the CD30 molecule is currently unknown; recently, however, 
Del Prete and co-workers (1995) have demonstrated its association with the 
development (in differentiation or activation) of murine type 2T cells. The 
work was initially carried out in vitro and was then tested in vivo by measuring 
circulating levels of CD30 immunopositive T cells in atopic and nonatopic 
patients. The results showed that the presence of small numbers of circulating 
CD4+CD30+ cells in patients the type 2 allergic response characteristic of 
atopy. The CD4+CD30+ T cells were also shown to produce type 2 cytokines 
when stimulated with antigen. 
As Figure 3.17 shows, CD30 immunolocalisation was evident for a proportion 
of lymphocytes in a focal aggregate present in the keloid dermis (see Table 
3.2). Figure 3.18 is a CD30+ cell shown at higher magnification to confirm its 
cell surface expression. 
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Figure 3.17 A micrograph to illustrate the immunolocalisation of the cell 
surface marker CD30 in human keloid tissue (magnification x100, dilution 
1: 50, representative of n= 75) 
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Figure 3.18 A micrograph to illustrate the immunolocalisation of the cell 
surface marker CD30 in human keloid tissue at higher power (magnification 
x500, dilution 1: 50, representative of n=75) 
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Table 3.2: Quantitative data for the immunolocalisation of cell surface 
markers in normal human skin and keloid tissue. Results are expressed as the 
mean and standard error (f) of positively stained stained cells in n=4 tissues, 
10 fields of view per tissue (4mm2, x20). The Mann-Whitney U-test was used 
to investigate statistical significance (P < 0.05 = *) 
Region CD4 CD8 CD30 CD31 CD58 
NS, D 5.0±1.8 5.3±2.1 1.3±1.3 30.5±10.1 26.8±9.1 
























The challenge of selecting the most appropriate in vivo model with which to 
compare the isolated ̀ snap shots' (which were available as clinical samples) of 
wound healing abnormalities was demanding. 
Hypertropic scars and keloids are often discussed in the same breath, 
but so far it has been impossible to develop a model of the formation of either 
one. The major contributing factor preventing the development of the models 
is the general lack of understanding of exactly what the malfunction is which 
leads to the development of keloid (or hypertropic) scars. Added problems 
include the definition of keloid scars, which is still a source of controversy, the 
fact that even in known keloid-formers it is not clear that a keloid will form 
until it actually has (this is mainly because clinical observation is still the only 
absolute way to define and describe a keloid) and the mass of conflicting 
publications concerning the behaviour of keloid fibroblasts in culture and their 
heterogeneity. 
Keloid samples used in the investigation in this thesis varied in size, 
age, growth position and patient sex, age and skin colour. Studies were carried 
out using both frozen and wax embedded sections with n numbers ranging 
from 50-75 per experiment. Normal control samples were also taken from a 
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variety of patients; however, the sample region was usually the chest area (by 
nature of the cosmetic operations undertaken). 
Wound healing research has progressed from the early Nobel prize 
winning in vitro work carried out by Carrell (Carrell and Burows, 1910) to 
more specific, detailed in vitro work to establish fibroblast production of 
collagen and collagenase (Steams, 1940) and from linear, open (Stein and 
Keiser, 1971) and bum wounds (Horton et al, 1990) in vivo to sponge implants 
(Vilijanto, 1964) and chamber implants (Schilling et al, 1959). Every piece of 
work carried out has a role in the development of our current understanding of 
wound healing. Parameters commonly studied in vivo include wound breaking 
strength, hydroxyproline/collagen deposition and the nature and accumulation 
of wound fluid. In each case, the in vivo model should be selected carefully in 
order to study specific features. 
The study of cellular and matrix components and their interactions is 
best evaluated histologically (Cohen and Mast, 1990). The use of stains and 
antibodies allows the observation of processes in a `fly on the wall' manner, 
although quantitation is difficult. Absolute values of negative versus positive 
immunolabelling are almost beyond current histological techniques (Carter 
and Swain, 1997) but with careful execution comparisons can be made 
between different samples in the same experiment. 
112 
Chapter 3 
The murine air pouch model is not traditionally regarded as a wound 
healing model, this is particularly evident in the opinions held by clinicians 
and surgeons (an excellent review of wound healing and its models by two 
plastic surgeons omits it completely, Cohen and Mast, 1990). Whether or not 
an individual researcher considers it as such depends upon the definition used: 
the murine air pouch model features granulation tissue formation, wound 
contraction (and the presence of myofibroblasts), collagen deposition and 
injury resolution. What it does not feature is an open injury, reepithelialisation, 
blood loss and clotting etc. As Drs Cohen and Mast state, `A variety of 
investigative models are available for the study of wound healing, yet there is 
no single best model. Each study protocol must be designed with full 
recognition of the advantages and disadvantages of the model(s) to be used 
and the results must be interpreted accordingly' (Cohen and Mast, 1990). 
A central theme of this thesis was to use the murine air pouch model as 
a comparison with keloid samples, the model is appropriate for this approach 
because, as mentioned above, it features injury resolution. The aspects of 
healing which it does not feature, such as blood loss, clotting etc, are not in 
consideration in this particular study. The main reason for this is that the 
clinical samples necessary for such investigations (that is, samples taken at 
timepoints from injury to keloid formation) were unavailable. This approach, 
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however, does not assume that these aspects of wound healing are not relevant 
to keloid formation or propagation. 
3.30 OUANTITATION OF IMMUNOHISTOCHEMISTRY DATA 
As will be mentioned in Chapter 4, a computerised method of quantitation of 
immunocytochemical results was attempted using SeeScan. SeeScan is a basic 
form of light microscopical image analysis which permits the visualisation of 
the microscope stage (and slide) using a computer monitor. 
It is an excellent technique to aid quantitation in cell smears and cell 
fractions. The main problem with its use in the quantitation of cells within 
tissue sections is its inability to discern subtle variations in colour contrast of 
staining. This limitation is exacerbated by the fact that the monitor being used 
is usually black and white (it was in this case). 
Human keloid lesional tissue is dense and collagenous and is cradled 
on approximately 70% of its perimeter by human dermis, which is less dense 
and much softer in texture. In order to section through the full depth of the 
samples and not cause the dermis and lesion to separate, it is necessary to cut 
thicker sections than would be the case for other types of tissue. Unfortunately 
by adding thickness ('depth') to the sample, difficulty in visualisation is also 
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added. It becomes even more difficult to discern cell types when there are 
likely to be several layers of cells within the depth of tissue. It also becomes 
more difficult to discern variations in shade if the three-dimensional effect is 
emphasised by the added depth of the section. It was the combination of these 
difficulties coupled with the extensive heterogeneity of keloid samples which 
prevented the application of SeeScan in this thesis. 
In view of the emphasis placed on immunocytochemical analysis in the 
research for this thesis and the very individual nature of the samples to be 
studied, it was necessary to develop a suitable method for quantitation of 
positively stained cells. All murine and human samples were subjected to the 
quantitation method and the results for individual antibodies and samples are 
included in the relevant areas of text throughout the thesis. The method gives 
an approximation of the cells within an area which are positively stained for a 
given antibody. 
A further issue to address when using immunocytochemistry is how to 
nominate which cells can be considered to be ̀ positively stained'. In this case, 
this problem was compensated for (initially) by using various concentrations 
of antibody and analysing the optimum concentration for effective staining 
and minimum nonspecific background colouration. The actual dilution used in 
each experiment is given in brackets in the relevant areas of text throughout 
the thesis. Decisions of which individual cells were or were not positively 
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stained were taken with care and were based on the mean of sample 
populations (n numbers are given in relevant areas of text throughout the 
thesis). 
The results of the quantitative analysis are expressed as the mean and 
standard error of n=4,10 fields of view per tissue (randomly generated 
geography). The data were collected using a graticule, cells crossing the upper 
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Keloids are cutaneous lesions acquired through abnormal wound healing. They 
feature excessive collagen deposition (according to the general consensus), 
reduced collagen cross-linking (Di Cesare et al, 1990) and the absence of 
myofibroblasts (Ehrlich et al, 1994). The scar tissue outgrows the boundary of 
the original injury and can be itchy and painful (Rudolph, 1991). 
Numerous cytokines are known to be involved in normal wound healing 
and their general effects are well established (see Chapter 1). In abnormalities of 
repair, such as keloids, however, the information regarding the distribution and 
possible effects of these factors is scarce. 
Epidermal growth factor (EGF) is a mitogen for endothelial cells, T cells 
and epidermal cells (Knauer and Cunningham, 1983; Acres et al, 1985). It 
promotes the reepithelialisation of partial thickness wounds and increases wound 
strength in full thickness wounds (Nanney, 1990; Brown et al, 1988). EGF is 
present in most bodily fluids, although tissue concentration is usually low 
(Savage eta!, 1986). 
Platelet-derived growth factor (PDGF) is a chemoattractant for 
monocytes, fibroblasts and polymorphonuclear neutrophils (Deuel et al, 1982; 
Seppa et al, 1982). It stimulates wound healing in healing impaired genetically 
diabetic rodents and accelerates granulation tissue formation in full thickness 
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wounds (Greenhalgh et al, 1990; Hill et al, 1991). Platelets are the primary 
source of PDGF in wounds, although it is also released by macrophages, 
endothelial cells and stimulated fibroblasts (for review, see Antoniades, 1991). 
Basic fibroblast growth factor (bFGF) is a mitogen for keratinocytes, 
fibroblasts, promotes the division of endothelial cells and is a potent angiogenic 
factor (Gospodarowicz et al, 1986). It accelerates wound healing in genetically 
diabetic animals and downregulates collagen gene expression in keloid 
fibroblasts in vitro (Greenhalgh et al, 1990; Tan et al, 1993 *). bFGF is produced 
by fibroblasts, macrophages, endothelial cells and smooth muscle cells (for 
review, see Baird and Bohlen, 1990). 
Vascular endothelial growth factor (VEGF), also termed vascular 
permeability factor, is the most potent angiogenic factor known. It increases 
vascular permeability and induces the division of endothelial cells (Leung et al, 
1989). VEGF has been shown to be a potential therapeutic target for tumour 
treatment through experiments using monoclonal VEGF antibodies to block 
VEGF activity and tumour cell growth in vitro (Jin Kim et al, 1993) as well as 
work proving that tumour angiogenesis is regulated by VEGF activity in vivo 
(Plate et al, 1992). VEGF is produced by keratinocytes and tumour cells and is 
taken up by endothelial cells (for review, see Dvorak et al, 1995 x2) and induces 




Transforming growth factor-ß (TGF-ß) increases the deposition of 
extracellular matrix components, this is achieved by increasing the production of 
collagen and protease inhibitors and decreasing the production of proteolytic 
enzymes (Ignotz and Massague, 1986; Edwards et al, 1987). It accelerates the 
healing of full thickness wounds and of wounds impaired by steroids (Quaglino 
et al, 1990; Beck et al, 1991). TGF-ß is produced by platelets, lymphocytes, 
fibroblasts and macrophages (for review, see Roberts and Sporn, 1990). 
A comprehensive study (Appleton eta!, 1993) mapping the temporal and 
spatial immunolocalisation of EGF, bFGF, PDGF and TGF-ß in the murine air 
pouch model demonstrated that these cytokines, although possessing a wide 
range of properties, play intricate and intertwining roles in the healing process. 
In the murine air pouch model the initial release of cytokines is achieved through 
the degranulation of platelets in response to injury. It is suggested that continued 
release, which is required for wound resolution, is provided by macrophages and 
fibroblasts. Western blotting for VEGF in this model has shown a protein level 
peak around day 3, just prior to the timepoint of maximum vascularity (Appleton 
eta!, 1996; see Chapter 5). 
These two studies by Appleton and co-workers have illustrated that 
cytokines are important mediators in wound resolution, what has not been 
confumed, however, is their roles in abnormal healing pathologies. This study 
was designed to investigate the distribution of cytokine immunolabelling in 
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keloid tissues, in comparison to normal skin, and to extrapolate their influence in 
the aetiology of this condition. 
4.20 RESULTS 
4.21 Epidermal growth factor 
Immunoreactivity for EGF in normal human skin was restricted to the 
epidermis, hair follicles and some blood vessels. No immunoreactivity was seen 
in other cellular populations (see Table 4.1). 
In the dermis of the keloid tissues, intense labelling was evident in the 
acinus cells of the sebaceous glands, the endothelial cells of the blood vessels, 
hair follicles, epidermis and the myoepithelial cells of the sweat glands, EGF 
immunoreactivity was observed in some fibroblasts and macrophages (Figures 
4.1 a and b, 4.2 and Table 4.1). 
4.22 Platelet-derived growth factor 
The immunolocalisation profiles for PDGF in normal skin (see Table 4.1) and 
keloids was similar to that observed with EGF. 
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In general, staining intensity and distribution was greater in the keloid 
dermis than in the normal skin. Immunoreactivity was observed in the 
epidermis, hair follicles, sebaceous glands and the endothelial cells of some 
blood vessels of both skin types; merocrine sweat glands, macrophages and 
fibroblasts were labelled for PDGF in keloid dermis only (Figures 4.3,4.4 and 
Table 4.1). 
Table 4.1: Quantitative data for the immunolocalisation of cytokines in 
normal human skin and keloid tissue. Results are expressed as the mean and 
standard error (±) of positively stained stained cells in n=4 tissues, 10 
fields of view per tissue (4mm2, x20). The Mann-Whitney U-test was used to 
investigate statistical significance (P < 0.05 = *) 
Region EGF PDGF bFGF TGF-ß VEGF 
NS, D 14.5±2.9 43.3±4.6 47.3±2.9 8.3±2.2 27.0±5.1 




















(u, (termis and interlace; L, lesion; NS normal sample; KS, keloid sample) 
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Figure 4.1 Micrographs to illustrate the immunolocalisation of EGF, bFGF and 
TGF-%3 in keloid dermis. Preabsorption of the antibody results in complete 
amelioration of labelling a), whereas in b) serial sections labelled with EGF 
demonstrates specific localisation to the hair follicles of the keloid dermis (bar 
represents 20lon, dilution 1: 200, representative of n=75). In c) localisation of 
bFGF to the endothelial cells of a capillary in the keloid dermis is shown (bar 
represents Stan, dilution 1: 200, representative of n=75). TGF-, ß 
immunoreactivity associated with a sweat gland in the keloid dermis is 
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Figure 4.2 A micrograph to illustrate the immunolocalisation of EGF to sweat 




















Figure 4.3 A micrograph to illustrate the immunolocalisation of PDGF in 
keloid 
dermis (magnification x100, dilution 1: 200, representative of n=75) 
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Figure 4.4 A micrograph to illustrate the immunolocalisation of 
PDGF to a 
blood vessel in keloid tissue (magnification x100, dilution 
1: 200, representative 






4.23 Basic fibroblast growth factor 
Low levels of bFGF immunoreactivity were evident in hair follicles, sebaceous 
glands and blood vessels of the normal skin although not in other cellular 
populations (see Table 4.1). 
Intense immunolabelling was observed in dermal structures throughout 
the keloid tissues: hair follicles, sweat glands, sebaceous glands and blood 
vessels. Immunoreactivity was evident in most fibroblasts and macrophages in 
the keloid lesion and the dermis. bFGF was not detected in the epidermis of 
either skin type (Figures 4.1 c, 4.5,4.6 and Table 4.1). 
4.24 Vascular endothelial growth factor 
Immunoreactivity of VEGF in normal skin was confined to the endothelial cells 
of a minority of blood vessels and to low levels in hair follicles (see Table 4.1). 
Immunolabelling was not observed in other cellular populations in either tissue. 
The keloid tissue exhibited intense labelling for VEGF in the endothelial 
cells of most of the blood vessels in the dermis and lesion as well as hair 
follicles (see Figure 4.7 and Table 4.1). 
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Figure 4.5 A micrograph to illustrate the immunolocalisation of bFGF to a hair 
follicle and lymphocytes in keloid dermis ( magnification x50, dilution 1: 200, 
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Figure 4.6 A micrograph to illustrate the immunolocalisation of bFGF to a 











Figure 4.7 A micrograph illustrating the immunolocalisation of VEGF in keloid 
dermis. Specific localisation to the endothelial cells of capillaries is shown (bar 
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4.25 Transforming growth factor beta 
Low levels of immunoreactivity were observed in a minority of macrophages in 
the normal skin although not in other cellular populations (see Table 4.1). 
Immunoreactivity to TGF-ß was found in hair follicles, sebaceous glands 
and merocrine sweat glands in the keloid dermis. Macrophages and fibroblasts in 
the dermis exhibited labelling although fibroblasts in the keloid itself did not. 
TGF-ß immunolabelling was not detected the epidermis of either skin type 
(Figure 4.1d and Table 4.1). 
4.30 FURTHER ANALYSES 
Quantification studies using SeeScan were attempted, it was impossible, 
however, to discern cell types within tissue sections (see Chapter 1). Western 
blotting was also attempted, sample preparation, however, proved unsuccessful. 
This failure was caused by the collagenous nature of the keloid lesions; 
homogenisation, freeze-fracturing and vibrational-fracturing were all tested for 




Although much research has been carried out to elucidate the aetiology of 
keloids, the mechanisms involved in their formation are still unknown. Wound 
healing is a complex cascade of events initiated in response to injury. There is an 
acute inflammatory phase and the deposition of a provisional extracellular 
matrix, followed by collagen synthesis and wound resolution. Injuries resulting 
in keloid growth do not enter the final remodelling phase leading to normal scar 
formation. Many cytokines are important to normal wound healing, the relative 
quantities and distribution of these mediators reflect their roles in the resolution 
of injury. In this study cytokines were located inununohistologically within 
normal and keloid tissues with a view to suggesting their contribution to the 
continued expansion of the keloid lesion. 
EGF has many roles in the normal healing process. In the current study, 
increased levels of EGF were found in association with blood vessels, 
macrophages and fibroblasts in the keloid tissue. EGF acts as a mitogen for a 
variety of cell types and stimulates the release of collagenase (Delany and 
Brinkerhoff, 1992). It is possible that the distribution pattern observed in this 
study is consistent with EGF involvement in wound remodelling, through the 
production of collagenase. 
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The capacity of PDGF to induce both the synthesis and the breakdown of 
extracellular components provides it with a vital role in the resolution of 
wounds. The majority of macrophages and fibroblasts in the dermis of the keloid 
were immunolabelled for PDGF. These results suggest PDGF production by 
macrophages and the action of PDGF on the fibroblasts leading to the 
production of collagenase and collagen (Narayanan and Page, 1983; Bauer et al, 
1985). This hypothesis is corroborated by the finding that keloid fibroblasts 
display an enhanced response to PDGF as well as having elevated levels of 
PDGF a receptors (Haisa et al, 1994). This suggests both positive and negative 
roles for PDGF in the aetiology of keloids through the production of collagen 
and collagenase, respectively. 
bFGF promotes angiogenesis and upregulates the expression of VEGF 
(Stavri et al, 1995). Neutralising antibody treatment of bFGF in vivo has 
revealed its importance at the early stages of wound repair (Broadley et al, 
1989), it increases granulation tissue cellularity and reduces collagen content. A 
notable feature of the character of bFGF is that it is mainly intracellular, the 
mechanism of release is not known although it has been suggested that heat 
shock may achieve it (Jackson et al, 1992). The presence of substantial levels of 
bFGF in keloid dermis and lesion is consistent with the general stimulatory 
effects of bFGF on angiogenesis and VEGF expression. 
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Increased levels of VEGF in keloid samples indicates the development 
of new blood vessels, because when endothelial cell proliferation has ceased 
transcription levels are reduced (Breier et al, 1992). In tumours, VEGF release is 
stimulated by hypoxia and reduced oxygen tension (Jim Kim et al, 1993; Plate et 
al, 1992), it is not yet absolutely clear if keloids display evidence of hypoxia or 
necrosis, although it has been suggested (Kischer, 1992). In the case of keloids, 
therefore, the stimulus for VEGF expression is unclear. Given the abundant 
presence of cytokines in the keloid tissue, the stimulus in this case is more likely 
to be the presence of TGF-ß, bFGF and/or PDGF, each of which have been 
shown to increase the production of VEGF (Finkenzeller et al, 1992; Pertovaara 
et al, 1994; Stavri et al, 1995). There are many blood vessels throughout he 
keloid and the dermis, it is possible that the persistence of VEGF-stimulating 
growth factors could be the cause. 
TGF-ß increases the deposition of extracellular matrix components by 
increasing the production of collagen and protease inhibitors and decreasing the 
production of proteolytic enzymes (Ignotz and Massague, 1986; Edwards et al, 
1987). In keloid samples, TGF-ß was found in both fibroblasts and macrophages 
around the perimeter of the lesion. This observation is consistent with 
extracellular matrix deposition occurring in this area, suggesting the increase in 
growth of the lesion is propagated at its perimeter. Previous in vivo work has 
shown that dermal wounds treated with neutralising antibody to TGF-ß healed 
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without scarring, strongly suggesting that TGF-ß is required for scar formation. 
Those wounds treated with TGF-ß itself showed increased and more 
disorganised collagen content (Shah et al, 1992; Shah et al, 1995). Disorganised 
collagen arrangement caused by reduced cross-linking is present in keloid 
lesions although the enzyme, lysyl oxidase, which is required for the formation 
of mature cross-links is present and active (Di Cesare et al, 1990). It is possible, 
therefore, that the presence of increased levels of TGF-ß in the keloid lesion 
could account for the disordered collagen arrangement. 
The results of this study have demonstrated notably increased levels of 
bFGF and VEGF in keloid samples. Each of these cytokines alone or both of 
them acting synergistically, therefore, may be responsible for the increased 
number of blood vessels observed in keloid tissue. Because angiogenesis (new 
blood vessel formation) is a prerequisite for granulation tissue growth and, 
hence, wound resolution, this may indicate that the manipulation of bFGF or 
VEGF activity may be therapeutically useful. Furthermore, the results have 
demonstrated increased levels of TGF-ß. It is possibel that the action of this 
cytokine on extracellular matrix deposition may account for the large 




In vitro studies have shown that keloid fibroblasts display enhanced proliferative 
responses to EGF (Kikuchi et al, 1995) and TGF-ß (Russell et al, 1988), 
enhanced mitogenic responses to PDGF (Haisa et al, 1994) as well as displaying 
reduced collagen I production in response to bFGF (Tan et al, 1993*; Tan et al, 
1993). The results of this study suggest that an excess of these factors is present 
in keloid tissues. What is not clear is why this should be so; the propagation of 
the lesion, however, is clearly related to the continued cytokine presence. Cells 
produce mediators in response to some stimulus until that stimulus is lifted or 
until inhibition occurs through the action of another mediator. Keloid patients do 
not display effects of systemic upregulation of cytokines; indeed, not all injured 
areas will result in keloid formation in susceptible individuals. Although 
cytokines provide therapeutic opportunities, therefore, it is unlikely that they are 
the initial cause of keloid formation. It is necessary to identify the persistent 
stimulus responsible for the propagation of the lesion. 
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THE ROLE OF VEGF IN THE 




139 5.10 INTRODUCTION 
140 5.20 DOSING REGIME 
140 5.30 RESULTS 
140 5.31 Air pouch tissue dry weight (mg) 
141 5.32 Air pouch carmine content (µg) 
141 5.33 Air pouch vascularity (µg carmine/mg tissue dry weight) 
145 5.34 Clearing 
145 5.35 Immunolocalisation of CD31/PECAM 
145 5.36 Western blot (1mg/ml protein, 20µl/well) 
148 5.40 DISCUSSION 




The process of new blood vessel formation, angiogenesis, is critical to the 
propagation of certain pathophysiological conditions. One such well 
documented condition is the growth of tumours. In this particular instance, a 
lack of sufficient oxygen and nutrients in the centre of the tumour mass 
stimulates the growth of blood vessels into its centre. A number of cytokines, for 
example bFGF (Lobb et al, 1985; Schweigerer et al, 1987; Gospodarowicz, 
1990), have been implicated in this process and recently a potent endothelial- 
cell-specific mediator has provided fascinating new insight into angiogenesis. 
Vascular endothelial growth factor (VEGF), also termed vascular permeability 
factor (VPF), has been shown to be an absolute requirement for tumour growth 
(Jin Kim et al, 1993). Its mitogenic effects are restricted to endothelial cells 
(Leung et al, 1989), an attribute which makes VEGF unique among cytokines. 
As already mentioned, VEGF is angiogenic in vivo (Leung et al, 1989) and is a 
potent vascular permeability factor. These observations have prompted the 
suggestion that VEGF is the angiogenic factor which causes tumour growth and 
the vascular permeability factor which causes the persistent hyperpermeability of 
microvessels so characteristic of healing wounds (Klagsbrun and Soker, 1993). 
As documented in Chapter 4, blood vessels in keloid tissue display 
intense immunoreactivity for VEGF. Although it is widely accepted that keloids 
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feature extensive vascularisation, evidence of a role for angiogenesis in keloid 
formation and propagation has not yet been presented. Colville-Nash et al have 
previously demonstrated that angiogenesis is maximal at day 7 in the murine air 
pouch model (1995), and there is a lot of information available on the profile and 
distribution of various cytokines in this model (Appleton et al, 1993). In this 
study, therefore, the effects of neutralising antibody treatment to VEGF was 
examined using the murine air pouch model. 
5.20 DOSING REGIME 
Animals were dosed twice weekly, intraperitoneally, from day 1, with 10mg 
polyclonal antihuman VEGF, 10mg control immunoglobulin (Ig) G or 
phosphate buffered saline (PBS). The pouch was allowed to develop for 7 days. 
5.30 RESULTS 
5.31 Air pouch tissue dry weight (mg) 
Tissue dry weight was evaluated at day 7 (the timepoint at which angiogenesis is 
maximal in this model). Treatment with anti-VEGF resulted in a statistically 
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significant decrease in tissue dry weight (43.07 1 1.32mg) compared to IgG 
control (62.5 ± 2.85mg [P<0.05]) and PBS (59.82 ± 4.23mg; Figure 5.1). 
5.32 Air pouch carmine content (µg) 
Carmine content at day 7 for the PBS group was 87 1 8.7µg which was 
significantly increased (P<0.05) compared with the anti-VEGF group (24.1 ± 
Mpg). The carmine content of the anti-VEGF group was significantly 
decreased (P<0.05) when compared with the IgG control group (50.6 t 6.5µg; 
Figure 5.2). 
5.33 Air pouch vascularity (µg carmine/mg tissue dry weight) 
A decrease in vascularity accompanied that of tissue dry weight. Anti-VEGF 
treatment resulted in a significant reduction in vascularity from 0.78 f 
0.08µg/mg (P<0.05) in the PBS control group and 0.71 0.09µg/mg (P<0.05) in 
the IgG group to 0.42 t 0.07µg/mg in the treatment group (Figure 5.3). 
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Figure 5.1 A graph to show granulomatous tissue dry weight (mg) in the PBS, 
IgG and anti-VEGF groups (results are expressed as mean ± standard error, tor 
n=15 animals per group [experiment was carried out three limes, data 













Figure 5.2 A graph to show total carmine content (, ug) in the PBS, igG and anti- 
VEGF groups (results are expressed as mean ± standard error for n=15 animals 
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Figure 5.3 A graph to show vascularity (, ug carmine/mg tissue dry weight) in the 
PBS, IgG and anti-VEGF groups (results are expressed as mean f standard 
error for n=15 animals per group [experiment was carried out three times, data 
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The results of cedar wood oil treatment are shown in Figure 5.4: a) represents 
the PBS control sample; b) represents the IgG treated group; and c) represents 
the anti-VEGF treated group. It is clear from Figure 5.4 that anti-VEGF 
treatment has greatly reduced the number of blood vessels present in the day 7 
air pouch samples. In Figure 5.4c, the carmine is retained within the pre-existing 
blood vessels of the dermis. 
5.35 Immunolocalisation of CD31/PECAM 
Figure 5.5 shows that neutralising antibody treatment to VEGF has resulted in a 
marked reduction in the number of blood vessels present in the 
granulomatous/granulation tissue. 
536 Western blot (1mg/ml protein, 20µUwell) 
VEGF protein occurred at approximately 23kDa (as expected). VEGF was high 
up to 24 hours, still present at day 3 with levels at subsequent timepoints being 
significantly reduced. (Levels of protein were highest before day 3. ) VEGF 
protein was not detected in normal skin (Figure 5.6). 
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Figure 5.4 Micrographs to show the vascularity of skin samples of the murine 
air pouch model (a = PBS, b= IgG, c= anti-VEGF, magnification x200, 
representative of n=15) 
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Figure 5.5 Micrographs to show the immunolocalisation of PECAM in tissue 
from the murine air pouch model (magnification x100, dilution 1: 50, 
representative of n=25, a= control, b= anti-VEGFgroup) 
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Figure 5.6 A micrograph to show the Western blotting results for VEGF in 
tissues taken throughout murine air pouch tissues 
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5.40 DISCUSSION 
There is an increasing body of evidence to suggest that VEGF may be the most 
important factor in tumour angiogenesis. It is the only known endothelial-cell- 
specific mitogen (Leung et al, 1989), it is angiogenic in vivo (Leung et al, 1989; 
Klagsbrun and Soker, 1993) and treatment with anti-VEGF significantly reduces 
angiogenesis in a number of tumour models (Jin Kim et al, 1993). This study 
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shows that anti-VEGF treatment can also significantly reduce pouch tissue dry 
weight as well as suppress the vascularity in the murine air pouch model (and by 
inference, wound resolution). 
bFGF upregulates the expression of VEGF in vascular smooth muscle 
cells (Stavri et al, 1995) and these two cytokines act synergistically to induce 
endothelial cell proliferation (Pepper et a1,1992). Pepper et al also demonstrated 
that low levels of TGF-ß potentiate the actions of bFGF and VEGF, whereas 
higher levels of TGF-ß attenuate them (1993). Appleton et al have previously 
shown that bFGF is present throughout he air pouch model and that TGF-ß 
levels are low at day 3 but increase thereafter (1993). The results of this study, 
therefore, are consistent with active angiogenesis until approximately day 7 
followed by a reduction, possibly caused by the presence of increasing levels of 
TGF-ß, as the tissue resolves. Also, termination of endothelial cell proliferation 
results in a decrease of VEGF production (Breier et al, 1992); hence, the finding 
that VEGF protein is mainly present upto day 3 only, in this model, suggests 
active angiogenesis at that timepoint. Neutralising the action of VEGF from day 
1, therefore, would result in significant inhibition of angiogenesis. This 
hypothesis is corroborated by the observation that anti-VEGF treatment resulted 
in drastically reduced blood vessel formation (Figures 5.4 and 5.5). 
Much of the initial work on VEGF was carried out within the context of 
tumours and their growth. In the case of tumours, VEGF release is associated 
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with reduced oxygen tension and hypoxia in the centre of the growing mass. The 
stimulation of VEGF activity in wound healing is still not clear; Brown et al 
(1992) suggested that VEGF may be acting as a mitogen for endothelial cells in 
the wound bed and as a promoter of the deposition of an extravascular fibrin 
matrix via its vascular permeability abilities, but did not offer any suggestion as 
to what the mechanism of VEGF stimulation and release may be. 
The results here suggest that VEGF activity is a vital component of the 
resolution of the murine air pouch model. The inhibition of this activity resulted 
in a statistically significant reduction in vascularity and 
granulomatous/granulation tissue dry weight. Granulation tissue has an 
extensive neovasculature embedded within a loosely assembled matrix of 
collagens, fibronectin and proteoglycans. Fibroblasts within the granulation 
tissue acquire the ability to contract the collagenous matrix thus contributing to 
wound closure and healing. The formation of granulation tissue is an essential 
transitory stage in the progression to efficient healing, any inhibition of its 




The evidence provided by many studies indicates that VEGF is very important 
in the angiogenic process; a process that facilitates the continued growth of 
tumours in vivo and, as demonstrated by these results, influences 
granulomatous/granulation tissue development and resolution. Is it possible that 
VEGF is involved in the formation and/or propagation of keloid lesions? 
The results of immunocytochemical analyses of keloid tissues have 
revealed high levels of immunolabelling for bFGF and VEGF in the dermis and 
in the lesion; whereas TGF-ß was located only in the dermis and at the leading 
edge of the lesion, not actually within it where the growth of blood vessels 
would be occurring (Chapter 4). Blood vessels were found throughout the tissue 
and the majority were immunolabelled for bFGF and VEGF (characterisation of 
blood vessels was carried out using antibodies to CD31/PECAM; Chapter 3). 
VEGF activity in wounds quickly returns to normal levels within days of healing 
(Brown et al, 1992) and indeed VEGF is only expressed during active 
angiogenesis (Breier et al, 1992) as is confirmed by the results obtained in the 
murine air pouch model which show levels of VEGF activity building to day 7, 
the timepoint of maximum tissue dry weight, and decreasing at subsequent 
timepoints as resolution progresses. Keloid tissues, however, feature consistently 
high levels of VEGF protein throughout the extensive vascular network. This 
151 
Chapter 5 
evidence suggests that active angiogenesis is still ongoing in scars which may be 
several years old. 
The abundant presence of angiogenic factors (bFGF, TGF-ß and VEGF) 
in keloid samples suggests a role for them in the propagation of the lesion. It is 
possible, therefore, that therapeutic neutralisation of local VEGF activity could 
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The dermis of keloid scars features increased numbers of T cells in 
comparison with normal skin and abnormal scars (see Chapter 3; Martin and 
Muir, 1990). The greatest concentrations of lymphocytes are observed at the 
invading edge of the lesion and in association with hair follicles. The lesion is 
composed of disordered collagen bundles (Hunter and Finlay, 1976) 
interspersed with fibroblasts (Matsuoka et al, 1988) and mast cells (Craig et 
a1,1986). 
In normal wound healing, T cells are involved in the modulation of 
fibroblastic activity. This has been demonstrated in vivo by depleting mice of 
T cells, which resulted in impaired collagen deposition and decreased wound 
breaking strength (Peterson et al, 1987). 
It is possible to define T cell subsets by their pattern of cytokines 
secreted in response to antigen (for reviews, see Romagnani, 1991; Carter and 
Dutton, 1996). These subsets are termed type 1 and type 2 and have been 
identified for CD4+, CD8+ and yS T cells. Type 1 CD4+ cells produce 
interleukin (IL)-2 and interferon (IFN)-y and inhibit the development of type 2 
cells; type 2 CD4+ cells produce IL-4 and IL-5 and inhibit the development of 
type 1 cells (Goldman et al, 1991). (The situation for CD8+ and yS T cells is 
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more complex and will not be dealt with here, although it is probably suffice 
to say that CD8+ cells are involved in immune suppression. ) 
IL-10 is produced by type 1 and type 2 human CD4+ cells, it inhibits 
type 1 CD4+ cell development both alone and in synergy with IL-4 (Yssel et 
al, 1992; Powrie et al, 1993; Del Prete et al, 1993). 
In vitro activated mast cells enhance fibroblast proliferation and 
collagen production (Abergel et al, 1985; Levi-Schaffer and Rubinchik, 1995) 
possibly via histamine release (Sandberg, 1962). Keloid samples contain 
elevated levels of histamine and increased blood vessels in the dermis. This 
suggests a role for histamine and blood vessels in the propagation of keloid 
lesions (Hakanson et a1,1969; Cohen et al, 1972; Kischer et a1,1978; Smith et 
al, 1987). 
Human skin mast cells produce IL-4 in response to immunoglobulin-E- 
dependent stimulation (Bradding et al, 1992). It has been suggested that this 
activity triggers the development of CD4+ cells of the type 2 subset (Bradding 
et al, 1992), although natural killer cells and basophils have also been 
implicated (Bendelac, 1995; Porcelli and Modlin, 1995; Yoshimoto et al, 
1995). IL-4-transgenic mice develop high levels of circulating 
immunoglobulin E (Tepper et al, 1990), whereas IL-4-deficient mice cannot 
produce IL-4 nor do they develop IgE responses (Kuhn et al, 1991). In a 
random study carried out on 1206 individuals, a positive correlation was 
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shown between the level of- IgE-associated responses and keloid formation 
(Smith et al, 1987). 
There is overwhelming evidence in favour of an immunological 
component to keloid formation (for review, see Placik and Lewis, 1992); 
however, the initiation and perpetuating force are unknown. This study was 
designed to investigate the distribution of lymphokines (IL-2, IL-4, IL-10 and 
IFN-y) in keloid tissue and to propose their roles in the formation and 
propagation of the lesion. 
In order to speculate on the roles of these mediators in abnormal 
healing it was necessary to further investigate their roles in an animal model. 
Immunohistochemical analysis was carried out on tissues from the murine air 
pouch model at different stages of resolution. It was intended that 
demonstrating the presence or absence of these four lymphokines, as well as 
their patterns and relative distribution, would provide further evidence of their 
roles in normal resolution and that the insight gained could be employed to 
further explain the cause and exacerbation of keloids. 
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6.20 MURINE AIR POUCH MODEL TISSUE RESULTS 
6.21 Interleukin 4 
Immunolabelling for IL-4 at day 3 was restricted to hair follicles, at day 7 
additional immunoreactivity was evident in lymphocytes in the area of 
granulomatous/granulation tissue adjacent to the skeletal muscle layer. This 
gradual increase in positivity continued through to day 14, with labelling of 
fibroblasts and lymphocytes in the granulation tissue. The epidermis and hair 
follicles in the dermis also displayed immunoreactivity at day 14. Levels of 
IL-4 reached a peak at day 21, with increasing numbers of lymphocytes and 
fibroblasts labelling. Immunoreactivity had reduced throughout the tissue by 
day 28 and levels were comparable to those at day 7 (see Table 6.1). 
6.22 Interleukin 10 
As was the case for IL-4, immunoreactivity for IL-10 at day 3 was restricted to 
hair follicles. Lymphocytes in the area of granulomatous/granulation tissue 
adjacent to the skeletal muscle were immunolabelled at day 7, as were dermal 
hair follicles. By day 14, fibroblasts, macrophages and lymphocytes in the 
granulation tissue were intensely labelled, numbers were higher than those for 
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IL-4 at the same timepoint. A further increase in positivity was evident at day 
21 with fibroblasts in the lower region of the granulation tissue and with 
lymphocytes, macrophages and blood vessels in the upper region of the 
granulomatous/granulation tissue being strongly labelled. This pattern of 
distribution remained consistent through day 28 (see Table 6.1). 
6.23 Interferon gamma 
By day 3 immunoreactivity was evident in hair follicles and lymphocytes in 
the area of granulomatous/granulation tissue adjacent to the skeletal muscle. 
By day 7, IFN-y levels had decreased throughout he tissue with only the hair 
follicles displaying positivity. There was an increase in immunoreactivity at 
day 14 to approximately equivalent levels to those at day 3 although, in 
contrast to the distribution at the earlier timepoint, labelled lymphocytes were 
located in the lower area of the granulomatous/granulation tissue. This 
increase in positive labelling continued throughout the remaining timepoints, 
with fibroblasts in the upper region and lymphocytes in the lower region of the 
granulation tissue displaying intense positivity (see Table 6.1). 
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6.24 Interleukin 2 
Of the four lymphokines studied only IL-2 was present in control skin 
samples, and in this tissue its distribution was restricted to the epidermis. 
Dermal lymphocytes, hair follicles and the epidermis displayed 
immunoreactivity for IL-2 at day 3. Levels remained consistent at day 7 
although the distribution had altered to include a few dermal blood vessels and 
granulomatous/granulation tissue lymphocytes. Immunoreactivity for IL-2 
reached a peak at day 14 and levelled off at day 21, with lymphocytes and 
blood vessels in the granulation tissue being labelled as well as dermal 
lymphocytes, hair follicles and the epidermis. By day 28 the level and 
distribution of immunoreactivity had decreased to approximately that of day 7 
(see Table 6.1). 
159 
Chapter 6 
Table 6.1: Quantitative data for the immunolocalisation of lymphokines in the 
murine air pouch timecourse. Results are expressed as the mean and standard 
error (f) of positively stained stained cells in n=4 tissues, 10 fields of view 
per tissue (4mm2 x20). The Mann-Whitney U-test was used to investigate 
statistical significance (P < 0.05 = *) 
Day Region IFN-y IL-2 IL-4 IL-10 
3 D 51.0±5.6 25.5±4.0 8.3±1.3 16.5±2.6 
3 GT 20.3±1.7 11.5±1.7 2.3±1.3 2.0±0.8 
7 D 30.0f4.7* 22.5±8.4 8.3±2.2 28.0±3.6* 
7 GT 13.0±2.2* 14.8±2.5 14.3±3.0* 25.5±2.9* 
14 D 51.0±2.9 67.5±3.7* 24.5±5.6* 40.3±3.8* 
14 GT 29.5±5.9* 70.3±8.2* 50.5±3.7* 69.0±2.2* 
21 D 69.3±5.6* 69.5±5.2* 31.0±1.8* 37.3±5.9* 
21 GT 40.5±2.1* 72.5±5.6* 87.3±4.8* 82.0±3.7* 
28 D 89.0±5.9* 28.0±3.7 14.3±2.6* 30.8±3.9* 
28 GT 40.0±1.8* 21.8±3.3* 20.8±4.1* 84.0±3.7* 




These results illustrate the relative distribution of IL-2, IL-4, IL-10 and IFN-y 
in the context of a model of normal granulomatous/granulation, tissue 
resolution. Generally, in this model the levels of immunoreactivity for all four 
lymphokines was shown to be increasing through 7-21 days, this time period 
is associated with matrix remodelling. Fibroblast proliferation is maximal at 
day 7 with persistently high levels through to day 21 (Kimura et al, 1985). The 
same pattern is observed for lymphocytes (Chapter 3; Kimura et al, 1985) and 
the quantity of collagen fibres (Chapter 7; Kimura et al, 1985). Matrix 
remodelling requires the synergism of mediators that exert positive and 
negative effects on collagen deposition and breakdown, the distribution pattern 
of the four lymphokines shown here is consistent with previous investigations: 
IL-2 is known to increase hydroxyproline content and wound breaking 
strength in vivo (Barbul et al, 1986); IL-4 stimulates fibroblast proliferation 
and collagen production (Fertin et al, 1991; Postlethwaite et al, 1992); IL-10 
and IFN-y have both been shown to behave as regulators of fibrosis; and, IFN- 
y inhibits collagen production by fibroblasts as well as stimulating collagenase 
release (Seder et al, 1992; Reitamo et al, 1994). 
As will be discussed in Chapter 7, IFN-y is important early in the 
murine air pouch model, and indeed it is present in a greater number of cells 
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compared with the three other lymphokines investigated here. Granstein et al 
(1989) demonstrated that the in vivo administration of IFN-y reduced the acute 
inflammatory response until approximately 72 hours after injury at which time 
the expected, although delayed, inflammatory response was evident. The 
group proved that this suppression was largely caused by angiostatic effects. 
Angiogenesis is maximal at day 7 in the murine air pouch model and these 
immunocytochemical results show that IFN-y levels are lowest at that 
timepoint. It is possible, therefore, that IFN-y is behaving as an anti- 
inflammatory agent at day 7. 
By day 28 there is a clear dichotomy in lymphokine presence: 
immunoreactivity for IL-10 and IFN-y is high; immunoreactivity for IL-2 and 
IL-4 is low. These findings are inkeeping with previous investigations of these 
particular lymphokines in wound resolution. It is possible that, at day 28, IL- 
10 and IFN-y are acting as antifibrotic agents, with IL-10 inhibiting collagen I 
production and IFN-y stimulating collagenase release, whereas IL-2 and IL-4, 
factors which would ordinarily increase collagen production and fibroblast 
proliferation, are at reduced levels. 
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6.40 HUMAN TISSUE RESULTS 
6.41 Interleukin 4 
Normal skin displayed immunoreactivity for IL-4 in the epidermis and hair 
follicles only (see Table 6.2). 
In the keloid dermis immunoreactivity for IL-4 was observed in the 
epidermis, hair follicles, mast cells, lymphocyte populations, fibroblasts and 
some blood vessels, a minority of blood vessels were also labelled in the 
keloid lesion. Fibroblasts within the lesion were not labelled for IL-4 (Figures 
6.1,6.2,6.3 and Table 6.2). 
6.42 Interleukin 10 
Immunoreactivity for IL-10 in normal skin was confined to hair follicles and 
the epidermis (see Table 6.2). 
The epidermis, hair follicles, lymphocytes, blood vessels and 
fibroblasts in the keloid dermis were all positively labelled. Fibroblasts in the 
keloid lesion did not display immunoreactivity for IL-10 (Figures 6.1a and b, 
6.4 and Table 6.2). 
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Figure 6.1 Micrographs illustrating the immunolocalisation of 
IL-4 and IL-10 
in keloid tissue. Preabsorption of the antibody results 
in complete 
amelioration of labelling a) whereas 
b) serial sections labelled with IL-10 
demonstrates specific localisation to hair 
follicles in the keloid dermis). In c) 
and d) localisation of IL-4 to mast cells and 
lymphocytes respectively is shown 
(bar represents 250µm, dilution 1: 100, representative 
of n=75) 
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Figure 6.2 A micrograph to illustrate the immunolocalisation of IL-4 to 
lymphocytes in the dermis of a keloid sample (magnification x100, dilution 







Figure 6.3 A micrograph to illustrate the immunolocalisation of IL-4 to 
lymphocytes in the dermis of a keloid sample at higher power (magnification 
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Figure 6.4 A micrograph to illustrate the immunolocalisation of 
IL-10 in a 
section taken through the epidermis and 
dermis of a keloid sample. Note the 
numerous positively labelled lymphocytes 
(magnification x50, dilution 1: 100, 
representative of n= 75) 
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6.43 Interferon gamma and interleukin 2 
Immunoreactivity for IFN-y and IL-2 was not seen in any cellular population 
in the keloid dermis or lesion (see Table 6.2). Positive labelling was seen in 
the control tissue, fibrocontractile capsule formed around silicone gel 
implants, which has been shown to be associated with delayed-type 
hypersensitivity, a type 1 response (Narini et al, 1995), thus proving the 
efficacy of the antibodies used. 
Table 6.2: Quantitative data for the immunolocalisation of lymphokines in 
normal human skin and keloid tissue. Results are expressed as the mean and 
standard error (f) of positively stained stained cells in n=4 tissues, 10 fields 
of view per tissue (4mm2, x20). The Mann-Whitney U-test was used to 
investigate statistical significance (P < 0.05 = *) 
Region IFN-y IL-2 IL-4 IL-10 
NS, D 2.0±0.8 10.5±3.9 23.5±2.9 36.8±4.0 
KS, D 3.5±1.3 4.5±1.7 116.5±4.7* 111.0±7.1* 
KS, L 3.0±2.4 1.5±0.6* 55.0±2.9* 112.5±8.9* 
(u, aetmis and interlace; L, lesion; NN normal sample; IS, Keloia sample) 
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6.44 CD30 cell marker 
Normal skin and control tissue were not labelled in any area. A proportion of 
lymphocytes (see Chapter 3 for CD4+ distribution) in the keloid dermis 
displayed positive immunoreactivity for CD30 (see Figure 6.5 and Chapter 3). 
Figure 6.5 A micrograph to show the immunolocalisation of CD30 to 
lymphocytes in keloid dermis. Specific immunoreactivity to CD30 is illustrated 
in a proportion of lymphocytes in keloid dermis (bar represents 65um, dilution 








Keloids feature abnormal collagen composition (DiCesare et al, 1990), 
extensive lymphocyte populations in the dermis (Martin and Muir, 1990) and 
increased mast cell and histamine content (Hakanson et al, 1969; Cohen et al, 
1972; Kischer et al, 1978; Craig eta!, 1986; Smith et al, 1987). The scar tissue 
outgrows the boundary of the original injury and as such can become 
disfiguring and incapacitating. Mowlem suggested in 1951 that there may be 
an immunological component to keloid formation (Mowlem, 1951). In spite of 
extensive research to test this hypothesis (Chytilova et al, 1959; Osman et at, 
1978; Yagi et al, 1979; DeLimpens and Cormane, 1982; Fasika, 1992), neither 
the mechanism nor the antigen have been identified. 
Cytokines have many important roles in repair processes (for reviews, 
see LeRoy et al, 1990; Lowry, 1993; Kovacs and DiPietro, 1994; Paul and 
Seder, 1994; Holtmann and Resch, 1995). IL-4 is produced by mast cells and 
activated CD4+ cells of the type 2 and type 0 subsets (Del Prete et al, 1991; 
Bradding et al, 1992) and type 2 CD8+ cells (Carter and Dutton, 1996). It is a 
pleiotropic cytokine with modulatory effects on diverse cell types including T 
cells, fibroblasts, endothelial cells, keratinocytes and mast cells (for review, 
see Vellenga et al, 1993). A profibrotic role for IL-4 is based on the 
observation that IL-4 stimulates fibroblasts to proliferate and secrete collagen 
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(Fertin et al, 1991; Postlethwaite et al, 1992). The presence of IL-4 in cultures 
of type 0 lymphocytes favours the development of the type 2 subset and 
inhibits the development of cells into the type 1 subset and the production of 
cytokines thereof (Abehsira-Amar et al, 1992). 
The results of this study of keloid tissue indicate intense 
immunolabelling for IL-4 in mast cells and lymphocytes. In conjunction with 
the presence of immunoreactivity to the CD4+ type 2 specific marker, CD30 
(Del Prete et al, 1995), this suggests that the CD4+ cells present in the keloid 
dermis are characteristic of type 2 cells. The production of IL-4 has been 
shown to increase immunoglobulin E levels (Pene et al, 1988). An increase in 
immunoglobulin E levels heightens the sensitivity of mast cells to 
degranulation when bound to antigen (Roitt et al, 1993), this results in the 
release of IL-4 and histamine (Sandberg, 1962; Bradding et al, 1992). Keloids 
feature elevated levels of both these mediators (Hakanson et al, 1969; Cohen 
et al, 1972; Kischer et al, 1978; Smith et al, 1987). Polarisation of the cellular 
immune system towards a type 2 response could ultimately maintain the 
fibrotic nature of the keloid lesion, via prolonged collagen production by 
fibroblasts under the influence of IL-4. The studies carried out in the murine 
air pouch model which demonstrates a decrease in IL-4 levels as resolution 
takes place reiterate this possibility. In normal wound healing, collagen III acts 
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as a scaffold for collagen I deposition (Nimni, 1983), a process which leads to 
remodelling and ultimately to wound resolution. 
Collagen I gene expression is inhibited by IL-10 in human skin 
fibroblasts (Reitamo et al, 1994) and collagen I production is inhibited in bone 
marrow cells (Van Vlasselaer et al, 1993). In the latter instance, no effect on 
proliferation was seen (for review, see Mosmann, 1994). The balance of 
collagen I and collagen III is disrupted in keloid tissue, with the ratio of type I 
to type III being higher than that of normal tissue (Lee et al, 1992). The results 
of this study show increased immunoreactivity for IL-10 throughout the keloid 
dermis in comparison to normal skin, possibly suggesting that the presence of 
increased levels of IL-10 may be an attempt by the tissue to rectify the 
increase in the ratio of type I to type III collagen seen in keloids. This study, 
therefore, provides evidence that the overproduction of IL-10 may be a 
countermeasure to interrupt the continued collagen I deposition which may 
otherwise contribute and exacerbate the ineffective wound resolution leading 
to the subsequent growth of the keloid lesion. 
IFN-y is produced by activated CD4+ cells of the type 1 subset, type 1 
CD8+ cells and natural killer cells (Reiter, 1993; for review, see Carter and 
Dutton, 1996). It inhibits collagen production by fibroblasts and can disrupt an 
established immune response, shifting it from type 2 to type 1 (Seder et al, 
1992), resulting in the inhibition of IL-4 production by lymphocytes. The 
172 
Chapter 6 
findings from the murine air pouch model experiments that IL-10 and IFN-y 
levels increase in the advanced stages of wound resolution (see murine air 
pouch model results), at a time when it is expected that fibrotic deposition is 
being curtailed, whereas increased levels of IL-10 and decreased levels of 
IFN-y are consistently found in keloids suggest that remodelling of the matrix 
is dysfunctional in keloid lesions. 
It is possible that the release of IL-10 is an attempt to inhibit excessive 
collagen I deposition, but that the collagen levels continue to increase in the 
absence of the IFN-y-stimulated production of collagenase. This study has 
shown that no cellular elements in the keloid dermis displayed 
immunoreactivity for IFN-y. Further evidence for immune system polarisation 
is provided by the lack of immunoreactivity for the type 2 specific product, 
CD30. Injections of IFN-y into keloid lesions provided positive results with 
diminished scar size (Granstein et al, 1990). These changes have been 
attributed to the inhibitory effects which IFN-y exerts on the production of 
collagen. The results of the investigation presented here (Chapter 6) suggest 
that it is possible that the lack of IFN-y may also effect the lymphocyte subset 
present within the tissue and, therefore, may prevent any further progression to 
normal wound resolution. 
The major findings of this study are the absence of immunoreactivity 
for cytokines characteristic of the type 1 subset, and the abundant presence of 
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I cytokines characteristic of the type 2 subset. Previous work has demonstrated 
that a proportion of the lymphocytes in keloids are of the T helper subset 
(Martin and Muir, 1990; Chapter 3). The results presented here extend these 
observations and have strongly suggested, by immunolocalisation of the CD30 
marker, that the CD4+ lymphocytes present are characteristic of the type 2 
subset. 
The lymphokines investigated in this study have many different actions in a 
variety of situations. In addition to the roles they play in the modulation of 
immune responses, they are intimately involved in the healing of wounds and 
in fibrotic deposition. These attributes implicate roles for IL-2, IL-4, IL-10 and 
IFN-y not only in the immunological component of keloid formation and 
propagation but also in the fibrotic component. Indeed, these results give rise 
to possible approaches for intervention. For example, if keloid formation is 
initiated by the type 2 polarisation of the immune response (perhaps caused by 
the persistence of antigen within the wound), a situation which would ensure a 
predominance of IL-4 and IL-10, suitable therapy could be to sufficiently 
reverse the immune response polarisation to aid successful healing. This could 
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be achieved by blocking IL-4 action, or by administering IFN-y (an approach 
already successfully employed in clinical trials, Granstein et al, 1990). 
It is interesting to note that Narini et al (1995) have shown that the 
presence of silicone gel in breast implants polarises the immune response 
towards the development of type 1 cells. Furthermore, it has recently been 
demonstrated that the topical application of silicone cream can dramatically 
improve the resolution of keloids (Wong et al, 1995). Taken together, these 
data suggest that driving the immune response away from type 2 
predominance, by the application of type 1 cytokines, can improve wound 
healing in keloids. 
It is difficult to test these hypotheses in the absence of an in vivo model 
of keloid formation and designing a suitable model is almost impossible as 
long as the nature of the antigen remains elusive. These results do help to 
further the understanding of keloid propagation, however, if not the initiation. 
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THE ROLE OF IFN-y IN THE 
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Interferon-gamma (IFN-y) has been proven to illicit many effects not only in 
vitro (Table 7.1) but also in vivo (Table 7.2), and the administration of anti-IFN- 
y has been shown to protect mice against the generalised Schwartzman reaction, 
initiated by lipopolysaccharide injection (Billiau eta!, 1987). 
Table 7.1: 
IN VITRO EFFECTS REFERENCES 
Inhibits wound contraction Dans and Isseroff, 1994 
Inhibits angiogenesis Sato et al, 1990 
Increases collagenase and 
glycosaminoglycan levels 




IN VIVO EFFECTS REFERENCES 
Decreases transforming growth 
factor ß mRNA levels 
Gurujeyalakshmi and Giri, 1995 
Decreases procollagen mRNA 
levels 
Gurujeyalakshmi and Giri, 1995 
Decreases collagen levels Granstein et a1,1989 
Inhibits wound closure Granstein et a1,1989 
Decreases neutrophil presence Granstein et a1,1989 
IFN-y has already been clinically tested to treat a range of abnormal 
cutaneous conditions (Granstein et al, 1990; Larrabee et al, 1990; Pittet et al, 
1994). A trial involving keloid patients and intralesional injections of IFN-y 
(0.01 or 0.1mg recombinant IFN-y into one lesion and diluent into another, 3 
times per week for 3 weeks, measurements taken at 8,15 and 22 days) provided 
evidence that this cytokine can influence the human cutaneous healing process. 
When administered to keloid sites (Granstein et al, 1990), lesional size was 
reduced by almost one third. Histological studies of the treated dermal area 
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revealed the presence of increased numbers of inflammatory cells accompanied 
by reduced quantities of thickened collagen bundles and reduced numbers of 
active fibroblasts. 
A similar trial in 1990 (Larrabee et al) involving keloids and hypertropic 
scars yielded comparable results. 
A further trial (Pittet et al, 1994), involved intralesional injections of 
IFN-7 (200µg twice per week for 4 weeks, with a 12 week post-dosing follow- 
up) into hypertropic scars and Dupuytren's disease nodules. Clinical 
observations included reduced lesional height and firmness, effects which 
persisted throughout the follow-up period. Histological studies showed a 
reduction in alpha smooth muscle actin expression in hypertropic scars 
(myofibroblasts are allegedly responsible for tissue retraction and excessive 
connective tissue production, the expression of alpha smooth muscle actin is an 
indirect indication of the presence of myofibroblasts). No change in collagen 
content was detected in response to treatment when collagen III and total 
collagen were studied histologically. In vitro experiments revealed 
antiproliferative effects on fibroblasts by IFN-y after 5 days of culture (IFN-y 
was added 24 and 96 hours after plating [passage 5] and was applied for 5 days). 
It was suggested in the study that IFN-y had reduced alpha smooth muscle actin 
expression, indicating a reduction in myofibroblast activity/presence, which had 
eased wound deformation. 
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In vivo experiments using a murine cutaneous healing model (Granstein 
et al, 1989) demonstrated that systemic administration of IFN-y (8.7x103 
units/hour over 14 days using a pump implanted subcutaneously or 
intraperitoneally) dampened the inflammatory response in early healing and 
delayed wound closure. It was suggested in this study that the inhibition of 
fibroblast proliferation and collagen production were responsible for the delay in 
wound closure. This study demonstrated that systemic administration of IFN-y 
could influence the resolution of cutaneous wounds in vivo. 
Normal wound healing involves the production of glycosaminoglycans 
which bind the wound fluid into a gel during the inflammatory stage of healing 
(days 0-3). The deposited glycosaminoglycans provide a temporary scaffold for 
neovascularisation, cell migration and the laying down of collagen fibres. 
Wound contraction generally begins at 7-8 days and serves to reduce the size of 
the area to be repaired. The fibroblastic stage often extends to approximately 3 
weeks and is essential to strengthen the wound via collagen deposition and 
maturation. 
IFN-y increases glycosaminoglycan (Duncan and Berman, 1989) 
production, is angiostatic (Sato et al, 1990; Tsuruoka et al, 1988) and inhibits 
fibroblast proliferation (Pittet et al, 1994), collagen production (Granstein et al, 
1989), alpha smooth muscle actin expression (Pittet et al, 1994) and wound 
closure (Granstein et a1,1989; Dans and Isseroff, 1994). 
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The murine air pouch model exhibits an acute inflammatory stage (0-3 
days), wound contraction (5-7 days) culminating in a remodelling and resolving 
stage (7-28 days). Following the immunocytochemical finding that IFN-y was 
absent for keloid samples (Chapter 6), although present throughout the resolving 
and remodelling stage of the air pouch model, an experiment blocking the 
activity of IFN-y and observing the subsequent effects on granulation tissue dry 
weight, glycosaminoglycan content and hydroxyproline (an index of wound 
reparative collagen deposition) content was designed. The aim being to collect 
data on the effects of IFN-y on resolution and to use this data to extrapolate its 
role in the mechanisms leading to keloid formation and propagation. 
7.20 DOSING REGIME 
Animals were dosed twice weekly, from day 1, with either lOgg/animal 
neutralising antibody to IFN-y (hamster anti-mouse; dose recommended by 
manufacturer), hamster immunoglobulin (Ig) G or phosphate buffered saline 




7.31 Air pouch tissue dry weight (mg) 
Table 7.3: Tissue dry weight (Mean ± standard error) 
PBS IgG anti-IFN-y 
Day 3 107.2±3.3 128.8±10 145±17.4 
Day 7 148±16 159.7±13.1 121.8±11.9 
Day 14 97.37±9 84.9±7.9 84.7±6.8 
Day 21 60.3±8 67.9±5.6 76.5±4.5 
Day 28 63.9±5 56.9±3 48±1.7* 
No statistically significant increase in tissue dry weight was achieved at day 3 
with anti-IFN-y treatment compared with IgG although there was a modest 
difference, raising the level almost to that of the IgG control group at day 7. 
There was a substantial reduction in dry weight with anti-IFN-y treatment at day 
7, although statistical significance was not reached. By day 28 the reduction 
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achieved statistical significance when compared with the IgG control group 
(Figure 7.1). 
Figure 7.1 A graph to show the profile of tissue dry weight (mg) in relation to 
the murine air pouch timecourse. Results are expressed as mean ± standard 
error (3-28 days, * P<0.05, n= 12-15 [experiment was carried out three times, 
data presented is that of a single experiment]). Black column = PBS, white = 
IgG, grey = anti-IFN-y 
00 1°0 
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7.32 Air pouch glycosaminoglycan (GAG) content (µg) 
Table 7.4: Glycosaminoglycan content (Mean :k standard error) 
PBS IgG anti-IFN-y 
Day 3 398±26 406±34 383±35 
Day 7 534±5 475±15 485±19 
Day 14 397±25 420±38 384±12 
Day 21 345±22 369±21 473±16* 
Day 28 443±37 439±25 484±21 
Blocking antibody treatment to IFN-y reduced the total glycosaminoglycan 
content compared with the IgG group at days 3 and 14 and increased it at day 7. 
By day 21 the day 14 decrease was reversed with a statistically significant 
increase in glycosaminoglycan content in the anti-IFN-y group compared with 
the IgG control. Levels of glycosaminoglycan at days 7,21 and 28 were 
approximately equivalent within the treated and untreated groups (Figure 7.2). 
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Figure 7.2 A graph to show the total glycosaminoglycan content (, ug) of 'murine 
air pouch tissues in relation to the timecourse of 3-28 days. Results are 
expressed as mean ± standard error (* P<0.05, n=12-15 [experiment was 
carried out three times, data presented is that of a single experiment]). Black 
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7.33 Ratio of glycosaminoglycan content : tissue dry weight (µg: mg) 
Table 7.5: Glycosaminoglycan content : tissue dry weight (Mean ± standard 
error) 
PBS IgG anti-IFN-y 
Day 3 0.37±0.02 0.33±0.05 0.29±0.04 
Day 7 0.38±0.04 0.31±0.03 0.42±0.4 
Day 14 0.42±0.04 0.54±0.08 0.48±0.04 
Day 21 0.63±0.045 0.56±0.05 0.61±0.05 
Day 28 0.74±0.1 0.81±0.1 1.01±0.042* 
The overall trend for the glycosaminoglycan : dry weight ratio was an increase 
throughout the time course in all groups, with statistical significance in the 
treatment group at day 28 compared with IgG. Neutralising antibody treatment 
to IFN-y reduced the glycosaminoglycan : dry weight ratio in comparison to the 




Figure 7.3 A graph to show the ratio of glycosaminoglycan content (ug) to 
tissue dry weight (mg) in murine air pouch tissues throughout the timecourse of 
3-28 days. Results are expressed as mean ± standard error (* P<0.05, n=12-15 
[experiment was carried out three times, data presented is that of a single 
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734 Air pouch hydroxyproline (HPr) content (µg) 
Table 7.6: Hydroxyproline content (Mean f standard error) 
PBS IgG anti-IFN-y 
Day 3 194.7±13.0 767±119 1456±66.6* 
Day 7 222±16 256±9.8 275±16 
Day 14 172.5±19 226±20.4 182±20 
Day 21 170±16 155.7±9 150±12.4 
Day 28 172.5±22.5 201.3±10 125.3±7.1 *
A statistically significant increase in tissue hydroxyproline content was observed 
at day 3 in the treatment group compared with the IgG group. Levels were also 
elevated at day 7 in comparison with the IgG control, although not significantly. 
Hydroxyproline content in the IgG group at day 14 was higher than that of the 
treatment group. At day 21 the anti-IFN-y treatment had marginally decreased 
hydroxyproline content compared with the IgG control. There was a statistically 
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significant decrease in hydroxyproline content in the treatment group compared 
with the IgG group (Figure 7.4). 
Figure 7.4 A graph to show total hydroxyproline (mg) content in relation to lime 
in the murine air pouch model. Results are expressed as mean ± standard error 
(3-28 days, * P<0.05, n=12-15 [experiment was carried out three limes, data 
presented is that of a single experiment]). Black column = PBS, while = IgG, 
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7.35 Ratio of hydroxyproline content : tissue dry weight (gg: mg) 
Table 7.7: Hydroxyproline content : tissue dry weight (Mean f standard error) 
PBS IgG anti-IFN-y 
Day 3 9±1.4 6.4±1.3 11.3±1.8 
Day 7 1.6±0.2 1.7±0.2 2.4±0.2* 
Day 14 1.8±0.15 2.7±0.25 2.3±0.34 
Day 21 2.1±0.14 2.3±0.2 1.86±0.25 
Day 28 
ILL- 
2.7±0.2 3.7±0.38 2.6±0.11 * 
Until day 14 the ratio of hydroxyproline : dry weight in the anti-IFN-y treated 
groups was elevated, when compared with the IgG control, reaching statistical 
significance at day 7. At days 21 and 28 the levels were lower in the treatment 
group than in the IgG control, although statistical significance was reached only 
at day 28 (Figure 7.5). 
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Figure 7.5 A graph to show the ratio of hydroxyproline content (gig) to tissue 
dry weight (mg) throughout the murine air pouch timecourse of 3-28 days. 
Results are expressed as mean ± standard error (* P<0.05, n=12-15 
[experiment was carried out three times, data presented is that of a single 












; qýfpAt hp anss9; : ; ua)uo. )ad II 
191 
ýNO c/ý .: 't NG 
Chapter 7 
7.40 DISCUSSION 
IFN-y is classically regarded as an antifibrotic cytokine (Kovacs and Di Pietro, 
1994). This is mainly because research has shown that it can enhance 
collagenase production (Duncan and Berman, 1989), thus preventing the 
deposition of excessive levels of collagen and it can increase hyaluronic acid 
levels (Granstein et al, 1989), a glycosaminoglycan which is abundant in foetal 
wounds (in foetal wounds, which heal without scar formation, hyaluronic acid 
constitutes the majority of the matrix; see, Siebert et al, 1990). There is also 
evidence that IFN-y is able to inhibit transforming growth factor ß production at 
mRNA level (Gurujeyalakshmi and Giri, 1995); the presence of which would 
otherwise contribute to scar formation (Shah et al, 1992), and in vitro and in vivo 
experiments have clearly demonstrated that both procollagen and collagen 
synthesis are inhibited by IFN-y. 
Collectively these attributes have elected IFN-y as the solution to all 
fibrotic maladies (Vilcek et al, 1985), and indeed clinical trials have proved 
promising. 
The aim of this study was to investigate the effects of anti-IFN-y on the 
content of glycosaminoglycan and hydroxyproline in the developmental and 
resolving phases of the murine air pouch model. Blocking the action of IFN-y 
can sufficiently downregulate the inflammatory response so as to protect mice 
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from the generalised Schwartzman reaction (Billiau et al, 1987). This is only 
achieved, however, because the inflammatory reaction is driven by IFN-y release 
in this model. Studies claiming that IFN-y treatment can normalise a disordered 
healing process, therefore, suggest that the absence of IFN-y is the pathological 
cause. Is it possible that the absence of IFN-y in keloid samples, as shown in 
Chapter 6, is the cause of the excessive fibrotic deposition so characteristic of 
these lesions? 
Neutralising antibody treatment to IFN-y markedly altered the tissue dry 
weight profile compared to controls (Figure 7.1). Maximum tissue dry weight in 
the treatment group was at day 3 and was approximately equivalent to the 
maximum tissue dry weight in the IgG control group at day 7. Tissue dry weight 
in the treatment group at day 21 was similar to the level in the IgG control group 
at day 28. Because of Home Office restrictions, the length of the experiment 
and, therefore, resolution in this model is taken to be day 28. Anti-IFN-y 
treatment caused a statistically significant decrease in tissue dry weight at that 
timepoint, however, which suggests that the wound was still resolving after 28 
days. 
On the basis of this single parameter, it would appear that blocking the 
action of IFN-y has accelerated progression through the model (wound 
resolution). This conclusion is consistent with the evidence that IFN-y 
administration delays healing in vivo (Granstein et al, 1989). In the same study, 
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the acute inflammatory response at 48 hours was greatly reduced in IFN-y 
animals and an increased response was seen at 72-96 hours as though the 
timecourse had ̀ shifted' or had been temporarily paused. Transmission electron 
microscopical analysis proved that this effect was caused by changes in local 
blood flow. This angiostatic, anti-inflammatory activity of IFN-y is also 
implicated in the experimental results presented in this chapter. Although no 
measurements were made, it is possible that blocking the action of IFN-y has 
hastened maximum tissue dry weight to from day 7 to day 3 via 
angiogenic/proinflammatory behaviour. 
Glycosaminoglycan content in anti-IFN-y treated groups was reduced at 
days 3 and 14, approximately equivalent at day 7 and elevated at days 21 and 28 
when compared with IgG controls. IFN-y has been shown to increase 
glycosaminoglycan levels in vitro, reduced levels in response to anti-IFN-y, 
therefore, as shown at the early timepoints, is expected. The elevation of 
glycosaminoglycan levels at days 21 and 28 in the treatment groups is in 
opposition to the findings of Granstein et al, 1989, who state that as connective 
tissue content falls from day 14 glycosaminoglycan content increases in 
experiments administering IFN-y to wounded mice. It is difficult to explain this 
anomaly; it is interesting to note, however, that keloid lesions and Dupuytren's 
nodules also contain higher concentrations of glycosaminolgycans than controls 
(Flint et al, 1978; Abergel et al, 1985*). Levels of the fibrotic cytokine 
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transforming growth factor ß are elevated at days 21 and 28 in the murine air 
pouch model (Appleton et al, 1993) and the presence of IFN-y inhibits the 
actions of transforming growth factor ß at the mRNA level (Gurujeyalakshmi 
and Giri, 1995). It is possible, therefore, that the inhibition of transforming 
growth factor ß action is lifted when IFN-y is blocked and so glycosaminoglycan 
levels increase. 
Figure 7.4 shows total hydroxyproline levels in samples, a quantity 
which broadly represents collagen content. Blocking IFN-y activity at day 3 
caused a significant increase in hydroxyproline levels. A more modest elevation 
was also present at day 7. At days 14,21 and 28 reduced levels of 
hydroxyproline were present in the treated tissues, the reduction was statistically 
significant at day 28. IFN-y reduces collagen production at mRNA level via the 
inhibition of transforming growth factor ß expression (Gurujeyalakshmi and 
Giri, 1995). Transforming growth factor ß levels are normally low at day 3 in 
this model (Appleton et al, 1993), an increase in hydroxyproline levels when 
IFN-y activity is blocked suggests that transforming growth factor ß has 
recovered reactivity and is stimulating the production of hydroxyproline. By 
days 21 and 28 the healing tissues are highly collagenous and of reduced size. 
Anti-IFN-y treatment caused a reduction in granulation tissue dry weight at these 
timepoints (Figure 7.1), with significance at day 28. When hydroxyproline levels 
were normalised for reduced tissue dry weight (Figure 7.5) it was evident that 
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anti-IFN-y treatment had not had significant effects. (Normalisation minimalises 
differences in hydroxyproline content because collagen accounts for the majority 
of the tissue dry weight at the later timepoints, Granstein et al, 1990. ) Although, 
therefore, Figure 7.4 suggests a reduction in hydroxyproline levels at days 21 
and 28, with anti-IFN-y treatment, there appears to have been no overall effect. It 
is important here to note that clinical analyses of keloid and normal skin samples 
have shown them to contain roughly equivalent values of hydroxyproline 
concentration/mg tissue dry weight content (Abergel et al, 1985). Figure 7.5 
illustrates that anti-IFN-y treatment increased the value of the hydroxyproline : 
tissue dry weight ratio at earlier timepoints, with significance at day 7, but 
decreased after day 14. This evidence further suggests that blocking the activity 




Clinical trials documenting reduced keloid lesion size with the administration of 
IFN-y injections have not yet included biochemical analyses of collagen content. 
Histological examinations indicate reduced quantities of thickened collagen 
fibres (Granstein et al, 1990) but no more. Therefore the actual mechanism of 
IFN-y action in these trials is unknown. The lack of an in vivo model of keloid 
formation makes intensive investigation of the mechanisms involved very 
difficult. Analysing glycosaminoglycan and hydroxyproline levels in a normal 
resolving model, as was done here, however, has suggested that a lack of IFN-y 
does not cause excessive fibrotic deposition, in fact, on the contrary, it 
accelerates healing. Although, therefore, IFN-y administration may be useful 
therapeutically, its effects on collagen levels do not provide evidence for 
prophylactic application. Indeed, Granstein et al reported that placebo and IFN- 
, y-injected excision sites of a keloid former revealed a keloidal regrowth in both 
areas, with the IFN-y-treated lesion of reduced size compared to the placebo- 
treated area (1990). 
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THE ROLE OF APOPTOSIS IN 
KELOID FORMATION AND THE 
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The balance between cellular proliferation and cell death is a vital component of 
both normal and abnormal biological processes. The balance is a fine one and it 
is not difficult to envisage the results of a malfunction in one or the other 
activity. There are numerous forms of cell death (for review, see Majno and 
Joris, 1995), many of which have roles in growth and maintenance (eg in 
embryonic development) whereas others have been shown to be involved in 
pathology (eg diphtheria, in which necrosis in the tracheobronchial epithelium 
leads to the discharging of a leathery, whitish pseudomembrane formed by 
leukocyte and fibrin accumulation). Exact definitions of particular types of cell 
death are not yet clear because of the wide range of physiological areas, cell 
types and stimuli involved. The subject is currently enjoying plenty of interest 
and special attention, however. 
Apoptosis is a form of cell death that occurs in a controlled manner and 
is characterised by the condensation of components of the cell, a process which 
is usually followed by phagocytosis by macrophages. It is a process that can be 
easily studied through the application of in situ end labelling (see Chapter 2); 
during apoptosis the cell DNA is broken down into multiple segments of 185 
base pairs which exposes molecular endings which are biochemically specific 
and can be identified routinely (Wyllie, 1980). 
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During normal wound healing, new tissue is formed which contains 
numerous tortuous capillaries (see Chapter 5) and extensive fibroblast 
populations embedded in a collagenous matrix, this is a transitional state which 
ultimately progresses to an acellular collagenous scar. It is obvious, therefore, 
that cellular proliferation and cell death are at the forefront of wound resolution. 
Previous work carried out in the murine air pouch model (Appleton et al, 
unpublished data) has illustrated that, in this model, at day 3 there are 
proliferating macrophages and fibroblasts in the granulomatous/granulation 
tissue area with macrophages also proliferating in the skeletal muscle, 
presumably traversing from the dermis. By day 5 there is a significant decrease 
in the number of inflammatory cells in the dermis generally with proliferating 
macrophages till evident in the upper area of the granulation tissue. The number 
and distribution of proliferating fibroblasts remains consistent throughout the 
timecourse. The results prompted the group to conclude that the major source of 
inflammatory cells is migration, followed by proliferation and further migration 
through the smooth muscle layer to the granulomatous/granulation tissue. 
After day 5 it is suggested that the newly-formed blood supply to the 
granulation tissue is the source of the remaining proliferating inflammatory cells. 
Once this migration and proliferation is over what happens to the inflammatory 
cells and fibroblasts? For fibroblasts, this question has been answered by 
Gabbiani and co-workers (Desmouliere, 1995). This group employed in situ end 
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labelling to demonstrate that, as the wound resolves and a scar develops, the 
number of fibroblastic and vascular cells undergoing apoptosis increases. They 
go on to suggest that 'this is the mechanism of granulation tissue evolution into a 
scar'. They go even further to suggest that pathological scarring, such as keloid 
formation, could result if these granulation tissue cells (fibroblasts and vascular 
cells) are not eliminated. 
The normal histology of keloid tissue reveals that the centre of the lesion 
is largely avascular and acellular, which is in contrast to the surrounding area of 
dermis which features a rich vascular supply and numerous cells of varying 
types. This study was designed to investigate the proliferation and apoptosis 
taking place in the keloid lesion and in the surrounding area, with a view to 
extrapolating their effects on keloid propagation. 
8.20 RESULTS 
8.21 Murine air pouch tissue apoptosis data 
In situ end 1abe11ina 
Using in situ end labelling, no apoptotic cells were found in control skin 
samples. By day 3 there were cells undergoing apoptosis in the basal layer of the 
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epidermis and hair follicles. Some apoptotic cells were present in the dermis but 
very few and of debatable lineage. By day 7a few apoptotic cells were visible in 
the upper area of the granulomatous/granulation tissue, possibly fibroblasts, a 
pattern which was repeated with increasing numbers throughout the remaining 
timepoints. Cells undergoing apoptosis were evident very close to blood vessels 
in the dermis from day 14 onwards, although it was difficult to conclusively 
discern if they were endothelial cells (Figure 8.1 and Table 8.1). 
Table 8.1: Quantitative data for the apoptosis of cells in tissue taken from the 
murine air pouch timecourse. Results are expressed as the mean and standard 
error (f) of positively stained stained cells in n=4 tissues, 10 fields of view 
per tissue (4mm2 x20). The Mann-Whitney U-test was used to investigate 
statistical significance (P = 0.05 = *). Groups are compared with day 3 data 
Day Region in situ 
3 D 11.5±1.3 
3 GT 1.0±0.8 
7 D 15.5±1.3* 
7 GT 19.0±1.8* 
14 D 15.8±1.3* 
14 GT 29.5±1.3* 
21 D 23.0±2.2* 
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21 GT 34.5±3.1 * 
28 D 46.3±3.6* 
28 GT 62.5±2.9* 
(u, aermis; ti 1 granulomatous/granulation tissue) 
Figure 8.1 A micrograph illustrating the presence of apoptotic cells in the hair 
follicles of tissue sampled at day 3 of the murine air pouch (in situ analysis; 
magnification x100; n=12-15) 














8.22 Human tissue proliferation data 
Proliferating cell nuclear antigen immunolocalisation 
Using immunolabelling with proliferating cell nuclear antigen (PCNA) 
antibodies, numerous proliferating cells were seen in the basal layer of the 
epidermis in both the normal and keloid samples. Almost no proliferating cells 
were present in the normal dermis. This is in contrast to the area of dermis 
adjacent to the keloid lesion featuring immunolabelled fibroblasts, although the 
positive cells accounted for only a minority of the total fibroblastic population. 
There were no proliferating cells in the lesion itself, although the morphology of 
the fibroblasts present was consistent with those immunolabelled in the dermis 
(Figure 8.2 and Table 8.2). 
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Figure 8.2 Micrographs to illustrate the immunolocalisation of PCNA to 
epidermal cells in keloid tissue (above), magnification x100 (dilution 1: 50, 
representative of n=25). Immunolabelling of a fibroblast at high power is shown 
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8.23 Human tissue apoptosis data 
In situ end labelline 
Using in situ end labelling, apoptotic cells in the normal human samples were 
restricted to the basal ayer of the epidermis. 
In the keloid dermis and epidermis, numerous cells displaying positivity 
were seen. No apoptotic cells were present in the more collagenous acellular 
regions of the lesion, although numerous positively labelled cells were evident in 
the keloid dermis. A small proportion of apoptotic cells, presumably endothelial 
cells, were observed in blood vessels of the dennis. Areas of necrosis were also 
present in the keloid dermis (Figure 8.3 and Table 8.2). 
Acridine orange staining 
Using acridine orange staining, a few apoptotic keratinocytes were seen the 
dermis of normal skin. 
Apoptotic keratinocytes were also present in the area of dermis adjacent 
to the keloid lesion, numbers of which decreased nearer to the lesion. Although 
apoptotic cells were observed at the interface between the dermis and the lesion, 
none were present in the centre of the lesion (Figure 8.4 and Table 8.2). 
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Figure 8.3 Micrographs to illustrate immunoreactivityfor DNA strand breaks in 
keloid dermis a), magnification x50 and the mid region of the lesion b), 
magnification xSO. Blood vessel endothelial cells undergoing apoptosis are 
shown in c), (magnification x500, representative of n=25). See over 
Figure 8.4 Micrographs to illustrate acridine orange staining in normal human 
dermis in a). Apoptotic cells present in keloid tissue are shown in b) and c) 
shows the area of keloid at the interface between the dermis and lesion. It is 
interesting to note the absence of apoptotic cells in the lesion and the presence 
of apoptotic cells in the keloid dermis. Apoptotic cells are stained red, 
nonapoptotic cells are stained green and background is stained black 
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Table 8.2: Quantitative data for the proliferation and apoptosis of cells in 
normal human skin and keloid tissue. Results are expressed as the mean and 
standard error (f) of positively stained stained cells in n=4 tissues, 10 fields 
of view per tissue (4mm2, x20). The Mann-Whitney U-test was used to 
investigate statistical significance (P = 0.05 = *) 
Region PCNA AO in situ 
NS, D 37.0±3.2 20.5±2.6 15.5±3.1 
KS, D 149.3±3.1* 205.5±7.6 * 136.5±41.9* 
KS, L 15.0±4.1* 29.0±8.8 4.3±3.2* 
(U, dermis and interface; L, lesion; NS, normal sample; KS, ieloid sample; YLNA, prouterat ng cen 
nuclear antigen; AO, acridine orange; IS, in situ) 
8.30 DISCUSSION 
It seems inevitable from accrued knowledge that the fibrous keloid lesion is 
formed with the involvement of apoptosis. Gabbiani and co-workers 
(Desmouliere et al, 1995) documented that as a wound resolves and a scar forms 
the number of fibroblastic cells undergoing apoptosis increases. The results 
presented here of apoptotic analyses in the murine air pouch model reiterate this. 
The area in the centre of the keloid lesion is largely acellular and avascular 
whereas the dermal area contains fibroblasts and large numbers of lymphocytes 
and blood vessels, as does the interface between the two. This study was 
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designed to investigate whether visualising those cells which are proliferating or 
apoptosing, and their relative positions, could provide clues to the mechanisms 
involved in the formation and propagation of keloid lesions and to compare the 
data to that of the murine air pouch model. 
The results demonstrated that, although numerous lymphocytes and 
fibroblasts were present in the dermis of the keloid samples, only a small 
proportion of the fibroblastic population were positive for PCNA. This suggests 
that migration of lymphocytes, rather than proliferation, is responsible for their 
abundant presence in the keloid dermis. This hypothesis is consistent with 
previous suggestions that an endogenous antigen is the persistent driving force 
of keloid development. Indeed, if an antigen were resident in the skin, which 
was stimulating the migration of lymphocytes to the area, its prolonged presence 
would explain the apparent uninterrupted cycle of cytokine production and 
fibrotic deposition. There have been some suggestions as to the nature of the 
antigen, for example keratin, melanin and sebum (for reviews, see De Limpens 
and Cormane, 1982; Placik and Lewis, 1992), but there has been no 
confirmation yet. 
Although in vitro data has not clearly indicated increased proliferation 
rates for fibroblasts derived from keloid lesions compared with those derived 
from normal human skin samples, a study claimed that keloid fibroblasts do 
indeed proliferate at a higher rate than do normal fibroblasts (the study was 
211 
Chapter 8 
carried out using PCNA antibodies; Nakaoka et al, 1995). The latter study was 
flawed, however, because it was assumed that the fibroblasts at the centre and 
edge of the lesion were of the same phenotype. The results presented here clearly 
show that proliferating fibroblasts are restricted to those areas associated with 
dense lymphocyte populations and vascularity, and not to the central region of 
the lesion. This is consistent with the findings of Chapters 4 and 6 which 
indicate that the area associated with fibroblast proliferation is also an area rich 
in numerous cytokines and growth factors, whereas the centre of the lesion is 
not. Unfortunately, with the presence of heterogeneous cellular populations and 
the intricate interplay of numerous mediators in vivo, interpretation of in vitro 
data must be done very carefully. Again the absence of an animal model of 
keloid formation is a major problem. 
Hypoxia in keloid lesions has been suggested by light and electron 
microscopy (Kircher, 1992), a situation that could lead to the production of 
vascular endothelial growth factor (VEGF), as shown in tumours (Schweiki et 
al, 1992), and the induction of apoptosis. The results presented in Chapter 4 
establish that keloids samples display increased immunoreactivity for VEGF and 
the results in Chapter 5 suggest that VEGF could be important in the resolution 
of wounds. Apoptosis and VEGF localisation was confined to the blood vessels 
in the region of keloid close to the dermis, whereas neither apoptosis nor 
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necrosis was seen in the centre of the lesion. It is possible, therefore, that blood 
vessel regression in the lesion is apoptosis dependent. 
The results obtained in the murine air pouch model confirm the 
suggestion that apoptosis occurs naturally during the resolution of injury; and 
the results in human samples are inkeeping with Kischer's proposal that 
apoptosis may occur during the transition from granulation tissue resolution to 
scar formation in keloids as well as in normal scars (1992). Also demonstrated 
here (through the study of human samples) is that it is possible that proliferation, 
apoptosis and necrosis can proceed simultaneously with distinct roles. It is 
possible that as the keloid matures, apoptosis and necrosis remove certain 
cellular populations which results in the characteristic avascular, fibrotic lesion; 
whereas, the proliferation of fibroblasts in the dermis propagates the growth and 




By observing the origin (proliferation) and demise (apoptosis and necrosis) of 
particular cell types, as well as their relative locations, it is possible to 
hypothesise their roles in the aetiology of keloids. The results presented in this 
chapter are largely consistent with those from previous chapters: although 
keloids are an abnormal form of wound resolution, those mediators present and 
the characteristic pattern of cellular distribution and lesional growth suggest a 





9.10 SUMMARY OF FINDINGS 
The results of immunolocalisation studies suggesting the presence and distribution of CD cell 
surface markers in keloid tissues were documented in Chapter 3. CD3 1, the marker strongly 
expressed by endothelial cells, was immunolocalised in association with blood vessels 
throughout the keloid lesion. CD31 is also expressed by some macrophages, it was assumed 
that the few isolated cells immunolabelled for CD31 in the keloid tissues were macrophages. 
These cells were dotted around the keloid dermis in low numbers. 
CD58 is a more selective macrophage marker. In keloid tissues, CD58+ cells were 
found by immunolocalisation to be evenly distributed around the dermis with some also 
present ̀ buried' in the masses of lymphocytes so characteristic of keloid tissues. There were 
no CD58+ cells in the keloid lesion itself. 
The characterisation of the many lymphocytes present within the keloid tissues was 
attempted using immunolocalisation of CD4 and CD8 cell surface markers. CD4 is associated 
with the recognition of antigens bound by MHC class II molecules, CD8 is associated with 
the recognition of antigens bound by MHC class I molecules. The majority of lymphocytes in 
the keloid dermis were immunolocalised to be CD4+, although there were also small groups 
present throughout the tissue. Numbers of CD8+ lymphocytes were also substantial, although 
reduced in comparison with CD4+ cell numbers. 
The CD30 cell surface marker has been documented to be preferentially expressed by 
type 2 CD4 cells. Immunolocalisation studies suggested that a proportion of lymphocytes 
present in the keloid dermis were labelled for CD30. 
These results have suggested the following detailed description of the cellular nature 
and structure of keloid tissues, which has previously been unavailable. The keloid dermis 
------- 215 
Conclusions 
contains aggregates of large numbers of lymphocytes (in comparison with normal skin) some 
of which are CD8+, the majority of which are CD4+. Individual lymphocytes are also present 
scattered around the tissue, particularly in association with hair follicles and the invading 
edge of the keloid lesion. In addition to the classification of the lymphocytes as CD4+ or 
CD8+ a number are characterised as being of the type 2 subset through the 
immunolocalisation of the CD30 cell surface marker. The keloid dermis is extensively 
vascularised, the lesion does not contain a vascularised network. Macrophages are present 
buried in the groupings of lymphocytes in the keloid dermis, although there are a few 
individual cells present in isolation. The lesion itself does not contain macrophages. 
The results of immunolocalisation studies using antibodies to cytokines were documented in 
Chapter 4. Cytokines have been shown to be the foremost mediators involved in intercellular 
communication. Enhanced presence of EGF, PDGF, bFGF, VEGF and TGF-ß was displayed 
in keloid samples (compared with normal samples). Distribution of labelling was generally 
confined to the dermis of the samples and structures therein. Most notably, distribution of 
TGF-ß immunolocalisation was evident around the perimeter of the lesion. It is generally 
accepted that the growth of the keloid lesion occurs from the perimeter. It is also generally 
accepted that TGF-ß is a powerful force in the deposition of fibrotic and scar tissues in any 
healing situation. These results strongly suggest, therefore, that TGF-ß is probably involved 
in the excessive fibrotic deposition present in keloid samples. The localisation pattern of 
VEGF in keloid tissues (VEGF is only expressed during active angiogenesis) suggests a 
greatly increased number of blood vessels in the dermis (compared with normal samples), the 
lesion does not display VEGF immunoreactivity (which is consistent with the localisation 
pattern of CD31 shown in Chapter 3). 
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The in vivo experiments documented in Chapter 5 using antibodies to neutralise the activity 
of VEGF showed that the presence of VEGF (and hence angiogenesis) is a strong driving 
force in the development of granulomatous/granulation tissue and its resolution. As 
mentioned above, the dermal area of keloid samples features elevated levels of VEGF (in 
comparison with normal samples). This suggests that, in the same way that TGF-ß is 
probably involved in the deposition of fibrotic and scar tissues in keloids, VEGF is probably 
involved in the development of the extensive vascular network present in the keloid dermis. 
And that the abundance of this angiogenic factor plays an active role, regardless of the age of 
the keloid, in lesional propagation. 
w 
The results of immunolocalisation studies documented in Chapter 6 suggest that type 2 
lymphokines (ie IL-4 and IL-10) are present in large quantities in keloid samples (in 
comparison with normal samples) and that type 1 lymphokines (ie IL-2 and IFN-y) are absent. 
Added evidence suggestive of the nature of the immune response underway in keloids is the 
presence of labelling for the type-2-characteristic cell surface marker, CD30. The results of 
immunolocalisation studies of IL-2,4,10 and IFN- y in murine air pouch tissues suggest that 
at the later timepoints when resolution is underway, levels of IL-10 and IFN-y are high and 
levels of IL-2 and 4 are low. These findings are in contrast to the levels of these mediators in 
keloid tissues, which revealed an approximately inverse pattern. 
It has previously been shown that IFN-y is a strong influence in the reduction of the size of 
fibrotic lesions, the in vivo experiments documented in Chapter 7 using antibodies to 
neutralise the activity of IFN-y showed that it does not play a central role in the resolution of 
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granulomatous/granulation tissue in this model. That is, it probably plays a late role in the 
resolution of injury. Indeed, immunolocalisation of IFN-y showed that it was more prominent 
in the later, rather than earlier, (resolution) phases of the murine air pouch model. 
Cellular proliferation analyses of keloid samples documented in Chapter 8 illustrated that 
very little proliferation is underway. Apoptosis analyses illustrated that there are enhanced 
levels of apoptosis taking place (in comparison with normal samples). Apoptosing fibroblasts 
are present only in those areas featuring lymphocytes and vascularity, fibroblasts in the keloid 
lesion (the few that exist) are not undergoing apoptosis. In addition to this, certain areas of 
vascularity around the perimeter of the lesion show evidence of endothelial cell apoptosis. 
It is recognised that immunohistological studies are sufficient to suggest the location of 
mediators in situ, but that they do not permit the absolute suggestion of mediator action, 
activity or effects. In order to investigate these aspects of mediator characteristics it would 
also be necessary to visualise mediator receptor and mRNA levels within the tissues. An 
alternative approach would be to perform multiple immunolocalisation labelling within the 
tissue samples. This technique would permit the localisation of the mediators as well as the 
relevant cell surface markers within the same tissue section, in order to provide further 
evidence of which cell types were positive for which mediators and where those cells were. 
Whenever suggestions are made in this thesis concerning mediator roles, therefore, it is 
necessary to consider the limitations of data provided by immunolocalisation experiments. 
Evidence collected in this thesis goes a long way towards providing an understanding of 
certain documented findings relevant to the formation and propagation of keloid lesions. The 
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following hypothesis is consistent with documented evidence and the results presented in this 
thesis: an injury occurs, the wound healing process is initiated and an antigen at the site is 
discovered by a patrolling lymphocyte. The lymphocyte journeys back to the bone 
marrow/thymus/lymph node and proliferates, the lymphocyte progeny migrate to the original 
site of antigen and release mediators in order to quell its effects. An unspecified event triggers 
an unspecified source of IL-4 (possibly mast cells) to become active, which reinforces that the 
lymphocytes are type 2 and that IL-2 and IFN-y, which may otherwise interfere with the 
immunological action against the antigen and inhibit excessive fibrotic deposition, are absent. 
The type 2 products stimulate the deposition of fibrotic components by fibroblasts and the 
production of themselves, meanwhile the antigen is still present, more lymphocytes migrate 
providing more type 2 mediators. Fibroblasts continue to respond to the presence of elevated 
levels of type 2 mediators and to the fibrotic cytokines (EGF, PDGF, TGF-ß) produced 
during normal resolution; wound healing and fibrosis deposition progress unabated at the 
same time that vascularisation continues under the direction of high levels of VEGF and 
bFGF. A mass of disorganised collagen has been deposited through the action of TGF-ß and 
fellow growth factors and the absence of the usually fibrosis-regulating IFN-y, inhibited by 
the action of the type 2 mediators, perpetuates this cycle. The unfortunate cycle of events is 
repeated as more lymphocytes migrate to the antigen and less IFN-y and IL-2 and more IL-4 
and IL-10 are produced. The levels of fibrotic growth factors present continue to rise, more 
deposition occurs and the area of tissue begins to grow larger than the wound site. 
The fact that lesional growth occurs from its perimeter suggests that the antigen is probably 
present in the dermis. The fact that the keloid grows beyond the boundary of the wound site 
suggests that the antigen is discovered anew at the invading edge of the reaction. 
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In vitro experiments using keloid fibroblasts do not confirm current knowledge of the 
character of that particular cell type. Is it possible that all fibroblasts throughout keloid 
formers are dysfunctional if the sufferer has normal fibroblastic processes elsewhere in situ? 
Evidence that the serum of keloid patients contained elevated levels of IL-4 and IL-10 
and reduced levels of IFN-y (as the keloid samples do) would certainly be alarming, more so 
if the patients were tested in the absence of a keloid lesion and the same results were to be 
obtained. If an individual were to permanently suffer from full-body dysfunctions of this 
magnitude, keloid growth would probably be a small manifestation of the problem when 
compared with accompanying effects. This seems to concur with the general belief that the 
problem is local to the site of keloid growth. 
Many questions remained unanswered, such as the following: 
Why do sufferers not develop keloid scars at every injury site? 
Why is the condition more common in black and oriental skins types than in white skin? 
Why is it more common in females than in males? 
It is suggested that the information provided in this thesis agrees with aspects of the 
commonly held hypothesis that keloid growth and regrowth are intricately entwined with an 
intense and complex immune response which has a local initiation. This thesis attempts to 
provide researchers with a ̀ map' of cell types, cytokines, proliferation and apoptosis in keloid 
tissues. As well as a clearer picture of the likely causes of the continued growth of keloid 
lesions. The in vivo results documented in this thesis provide some enlightenment of the in 
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situ effects of abnormal levels of VEGF and IFN-y, which is the case in keloid samples, on 
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